AU694093B2 - DNA virus ribozymes - Google Patents

Description

I

OPI DATE 20/02/95 APPLN. ID 47014/93 111111 iiNIHI llli AOJ P DATE 30/03/95 PCT NUMBER PCT/EP93 /01946 i li

IT)

(51) International Patent Classifirqitjon 6~ C12N 15/11, 9/00, 15/82, AO1H 5100 Al(11) International Publication Number: (43) International Publication Date: WO 95/03404 2 February 1995 (02,02.95) (21) International Application Number: (22) International Filing Date: PCT/EP93/01946 22 July 1993 (22.07.93) See W490 [FPJFR]: Campuc Uniumitan des Gkaf 21, avneds T -d4-6, F 631709 Allbikr GG~v9§9NWAfl1 SCI- (74) Agents: GUTMANN, Ernest et al.; Ernest Gutmann-Yves Plasseraud 67, boulevard Haussmann, F-75008 Paris

(FR).

(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR GB, GR, LE, IT, LU, MC, NL, PT,

SE).

Published With international search report.

IMnkl ATUA-1n, T Atr ')Anl (72) Inventors; and Inventors/Applicants (for US only): LENEE, Philippe [FR/FR]; 12, rue des Roches, F-63110 Beaumont (FR).

GRUBER, Wrwnique [fR/FR]; 44c, avenue Jean-Jaur~s, F-63400 Chaniali~res BAUDINO, Sylvie [FR/FR]; 2, Iotisscment-les-Volcans, F-63870 Orcines MASON, John [AU/AU]; Calgene Pacific PTY. Ltd., 16 Gipps Street, Coliingwood, VIC 3066 COMEAU, David [FR/FR]; 9, rue A.-Carrel, F-63000 Clermont-Ferrand REZA- IAN, Mohamad, Ali [IRAUI; 14 Sitters Memorial Drive, Burnside, S.A. 5066 (AUT). DRY, Ian, Barry [AU/AU]; I1I1 Kinston Avenue, Melrose Part, 5039 RIGDEN, Justin, Ellis [GB/AU]; 10 Chetwynd Street, West Beach, S.A. 5024 (AU).

I.-a A.41 (54) Title: DNA VIRUS RIBOZYMES

Z,

.1430bp

'C

HuaMV-aj 1075 23551 2056 2421 (57) Abstract The invention relates to a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target inRNA sequence transcribed from a DNA molecule associated with a DNA viru capable of infecting plant cells, wherein said catalytic region is capable of cleaving said target mRNA sequence thereby substantially reduci.n replication, infection and/or assembly of said DNA virus.

L, WO 95/03404 PCTIEP93/01946 1 DNA VIRUS RIBOZYMES The present invention is directed generally to synthetic ribozymes and their mutants and derivatives capable of catalysing cleavage of virus specified mRNA and, more particulary, DNA virus specified mRNA. The present invention further contemplates the use of these ribozymes in the generation of transgenic cells and, in particular, transgenic plant cells and plants capable of inhibiting infection by the viruses.

Viruses are the causative agents of a large number of serious and potentially serious diseases in humans, animals and plant. Plant viruses in particular have the potential to destroy or reduce crop yield and to otherwise have a deleterious effect on agricultural and horticultural industries to economically significant levels.

Particularly important viruses in this regard are the DNA viruses, including the Caulimo- and the Geminiviruses and two unclassified viruses, the subterranean Clover Stunt Virus (SCSV, Shu and helms, Virology, 1986, 167, 38-49) and Coconut Foliar Decay Virus (CFDV, Rohde et al, Virology, 1990, 176, 648-51). The geminiviruses are a group of small viruses which infect plant cells. They contain a single stand of circular DNA referred to as "virionsense" or "positive-sense" DNA of less than about 2900 base pairs. Upon infection of a host cell by a geminivirus, the viral coat protein is removed and a double stranded replicative form of DNA is synthesised comprising the virion-sense strand and a "complementary-sense" strand. Transcription occurs from both the virion-sense strand and from the L I, WO 95/03404 PCT/EP93/01946 2 "complementary sense" strand, giving rise to and sense RNA transcripts respectively.

Examples of geminiviruses include Maize Streak Virus (MSV), Bean Golden Mosaic Virus (BGMV), African Cassava Mosaic Virus (ACMV), Chloris Striate Mosaic Virus (CSMV), Tomato Yellow Leaf Curl Virus (TYLCV), Tomato Golden Mosaic Virus (TGMV), Beet Curly Top Virus (BCTV) and Tomato Leaf Curl Virus (TLCV) amongst many others (see also the viruses mentioned in table 1 below). These viruses cause economically important diseases in cultivated plants including leaf curling and other leaf distortion. TLCV in particular causes severe crop damage in northern parts of Australia and infected plants show symptoms similar to those caused by TYLCV in the Middle East and Europe. These tomato viruses are transmitted by the white-fly Bemisia tabaci and constitute a major disease problem worldwide. For convenience, and unless otherwise specified, TLCV and TYLCV are used interchangeably and reference herein to Israeli and Sardinian isolates of TLCV should be taken as TYLCV isolates. In gf'53al, "TLCV" refers to the Australian isolate.

Geminiviruses replicate in the nucleus of the infected cell and are thought to employ a rollingcircle mechanism similar to one used by the singlestranded DNA containing coliphages QX174) and certain Staphylococcus aureus and Bacillus subtilis plasmids. The other known plant viruses, including other plant DNA viruses, replicate via RNA intermediates.

Geminivirus particles accumulate in the nuclei of infected cells where DNA replication and virus assembly probably take place (Davies et al., J. Cell.

Sci (Suppl) (1987) 7 95-107). Their putative replicative forms are double-stranded covalently WO 95/03404 PCTIEP93/01946 3 closed circular DNA Ca. 2,7 Kb in chromatine-like structures and are likely to be the transcriptionally active forms of the virus (Abouzid et al., Mol. Gen.

Genet. (1988) 212 252-258). Based on host range and insect vectors, they may be conveniently divided into three subgroups the viruses which infect dicotyledonous hosts, have bipartite genomes and are transmitted by white-fly vectors Bemisia tabaci (Genn.) (ACMV, African Cassava Mosaic Virus (Stanley and Gay, Nature (1983) 301 260) TGMV, Tomato Golden Mosaic Virus (Hamilton et al, EMBO J. (1984) 3 2197) BGMV, Bean Golden Mosaic Virus (Horwarth et al, PNAS (1985) 82 3512) those which have monopartite genomes infect graminaceous hosts, and are transmitted by leafhopper vectors (MSV, Maize Streak Virus (Nigeria strain, Mullinaux et al., EMBO J.

(1984) 3 3063 Kenyan strain, Havel NAR (1984) 12 7359) DSV, Digitarian Streak Virus (Donson et al., Virology (1987) 161 160) WDV Wheat Jwarf Virus (Mac Dowell et al., EMBO J. (1985) 4 2173)) and those which possess monopartite genomes and have members which can be transmitted by leafhoppers (BCTV, Beet Curly Top Virus (Stanley et al., EMBO J. (1986) 1761) ToYDV, Tobacco Yellow Dwarf Virus (Maris et al., Virology (1992) 187 633)) or by whiteflies (TYLCV, Tomato Yellow Leaf Curl Virus (Israeli isolate, Navet et al., Virology (1991) 185 151 Sardinian isolate, Kheyr-Pour et al. NAT (1991) 19 6763), TLCV, Tomato Leaf Curl Virus (Australian isolate, Dry et al., J. Gen. Virol. (1993) 74 147)).

Due to economic importance of plant DNA viruses i and, in particular, geminiviruses, there is a need for disease resistance strategy to be developed.

One approach is to artificially suppress gene I expression by antisense RNA which targets WO 95/03404 PCT/EP93/01946 4 complementary RNA (Helene, C. Tolume, J. J. Biochim.

Biophys. Acta 1049:99-125, 1990 Vander Kro et al Biotechniques 6:958-976, 1988). Although antisense RNA has been successfully used in suppressing viral infection in bacteria and animal tissue (Helene, C Tolume, J. J. Supra), its use in plants has met with only limited success (Van Del Elzen, P. J. M. et al Plant Mol. Biol. 13:337-346, 1989 Powell, P A et al Proc. Nad. Acad. Sci. USA 86:6949-6952, 1989).

Indeed, transgenic plants expressing Cucumber Mosaic Virus (CMV) antisense RNA to different regions were generally not resistant to CMV infection, except one line, which paradoxically produced only very low levels of antisense RNA (Rezaian et al., Plant Mol.

Biol. (1988) 11 463). There was no proof that antisense was the cause of this resistance. In potato, antisense to PVX coat protein RiA sequence in transgenic plants protected against PVX only at low levels of inoculum (Hemenway et al., EMBO J. (1988) 7 1273).

Two major problems appear to be the quantity of antisense needed to cope with a replicating system that can rapidly produce large amounts of viral nucleic acid, and viral RNA is largely in the cytoplasm whereas antisense transcripts are produced in the nucleus.

With respect to geminiviruses, antisense technology has been applied to tobacco plants expressing an antisense DNA sequence of virally i .encoded AL1 gene of TGMV transcriptionally fused to a drug resistance gene (Day, A. G. et al Proc. Nad.

Acad. Sci. USA 88:6721-6725, 1991). Although transgenic plant lines expressing the antisense transcript showed reduced symptom development, it is possible that the transgenic plants were infertile i. ii-_ii _C WO 95/0340 4 PCTIEP93/01946 which would prevent large scale production of virus resistant plants.

In work leading up to the present invention, the inventors sought to overcome the disadvantages of the antisense approach to generating plant DNA virusresistant plants by employing the strategy of ribozymes.

Ribozymes are synthetic RNA molecules which possess highly specific endoribonuclease activity. In particular, they comprise a hybridising region which is complementary- in nucleotide sequence to at least part of a target RNA and a catalytic region which is adapted to cleave the target RNA. Ribozymes are well described by Haseloff J. and Gerlach L. Nature 334:586-591, 1988 and in International Patent Application No. W089/05852.

Howewer, despite the existence of ribozyme technology, heretofore, it has not been used on plant DNA viruses and in particular plant single stranded DNA viruses like geminiviruses. In fact, the success of the use of ribozymes on DNA viruses was unpredictable in view of their extremely complex replication and transcription mechanism, and the lack of information presently available concerning the compartmentalization of these different operations and the precise level of intervention of the different target sequences in the virus life nycle. For example, it is postulated that the replicase C 1 intervenes in the "rolling circle" replication step but not in the preceding step of the formation of the double-stranded replicative form of the virus (Elmer et al, Nucl.

Acid. Res., 1988, 16, p 7043-7060).

In accordance with the present invention, the inventors have successfully developed ribozymes capable of targeting plant DNA viruses thereby *i WO 95/03404 PCTEP93/01946 6 providing an economically viable and efficient means of controlling such viruses.

Accordingly, one aspect of the present invention contemplates a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target RNA transcribed from a DNA molecule associated with a DNA virus, wherein said catalytic region is capable of cleaving said target mRNA sequence thereby substantially reducing replication, infection and/or assembly of said DNA virus.

More particulary, the present invention is directed to a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence transcribed from a virion-sense DNA strand or a complementary-sense DNA strand of a plant single stranded DNA virus, wherein said catalytic region is capable of cleaving said target mRNA sequence thereby substantially reducing replication, infection and/or assembly of said DNA virus.

For convenience, reference to a plant single stranded DNA virus, includes reference to its double stranded replicative form.

In a preferred embodiment, the plant single stranded DNA virus is a geminivirus and the target mRNA encodes a protein essential for replication. By "essential" is meant a protein specified by the viral genome (or a complementary form thereof) and required or substantially required for a particular function such as replication, infection and/or viral assembly.

A decrease in the level of the essential protein results in -a reduction in the level of that function.

The decrease in the level of the particular function.

Preferably, the level of essential protein (or level it" WO 95/03404 PCT/EP93/01946 x of particular function) is 20 less, more preferably at least 30 less, even more preferably at least 45 less, still more preferably at least 55 less and still even more preferably 65-7 5% less and yet more preferably more than 85-90 less relative to the level of essential protein (or level of particular function) in the absence of the ribozyme.

Conveniently, the level of essential protein (or level of particular function) can be tested in vitro within the limits of biological variation in vivo.

Such a test, for example, can be by analysis of mRNA degradation products in vitro.

According to one preferred aspect of the present invention, there is provided a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence transcribed from a virion-sense DNA molecule of a geminivirus or a DNA molecule complementary to said virion-sense DNA molecule, said mRNA encoding a protein essential for replication of said geminivirus in a plant cell wherein said catalytic region is capable of cleaving said target mRNA sequence thereby substantially reducing replication of said geminivirus.

In an even more preferred embodiment, the target mRNA sequence is present in low abundance within the cell. An example of such a mRNA molecule is the transcript of the Cl gene or its equivalent in geniniviruses, such as in TLCV or TYLZV and its mutants, derivatives and variants. The single stranded DNA of TLCV contains six open reading frames (ORFs), two on the virion-sense strand and four on the complementary-sense strand of the replicative form DNA produced in leaf curl infected plants. Analysis of the viral mRNAs in infected plant cells reveal that the b I WO 95/03404 PCTIEP93/01946 8 mRNA encoding the Cl gene, which is essential for replication, occurs at lower abundance than the other mRNA transcripts specified by the TLCV genome.

Equivalent forms of the Cl gene include the genes LI, AL1 and AC1 and reference herein to the "Cl gene" is taken as including equivalents thereof.

Other targets include the C2, C3 and C4 transcripts which play roles in transactivation of virion-sense gene expression and spread of the virus, expression of the disease phenotype, and development of the disease respectively.

According to another preferred embodiment, the present invention is directed to a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence encoding the Cl gene of geminivirus and in particular TLCV and wherein said catalytic region is capable of cleaving said target mRNA sequence thereby substantialy reducing replication of said geminivirus g, TLCV).

In a preferred variant, the ribozymes of the present invention can be defined as nucleic acid compounds having endoribonuclease activity and being capable of inhibiting the replication, infection or assembly of a DNA virus, said compound comprising at least one unit, having the general formula 3' in which X and X' each represent, independently, a nucleotide sequence having at least 4 bases and being complementary to at least a part of either the viral genome, or the (-)sense RNA transcript of a DNA virus WO 95/03404 PCT/EP93/01946 9 Y represents the catalytic region of a ribozyme.

According to this variant, the target RNA is preferably the (-)sense RNA transcript, i.e. the mRNA originating from the transcription of the complementary sense strand of the double-stranded replicative form of the DNA virus genome, particularly a geminivirus. The sequences X and X' are therefore complementary to at least a part of the (-)sense RNA transcript (which is equivalent to being complementary to at least a part of the single stranded genomic

DNA).

The sequences X and hereinafter referred to as "hybridising arms" are sufficiently long to allow both stable hybridisation of the ribozyme to the substrate RNA, and efficient cleavage of the substrate. Normally, X and X' will have a length of at least 4 nucleotides each, and preferably at least 6.

The upper limit of the lengths of the hybridising arms is generally determined by the length of the targetted substrate and can be as long as 800 or 1000 bases or more. Preferred lengths are between 6 and 300 bases, for example 10 to 150. The complementarity of the hybridising arm to the substrate or to a part of the substrate, normally extends along the entire length of the hybridisisng arm.

The catalytic region of the ribozyme, is derived from any type of suitable ribozyme, for example "hammerhead" or "hairpin". These ribozymes are described in patent applications EP-A-321201 and EP- A-360257 respectively. Particularly preferred are "hammerhead" catalytic regions (see for example, figure and which will be described in detail tereafter.

J r qr c M WO 95/03404 PCT/EP93/01946 The ribozymes may be either "monoribozymes" possessing one single unit of the formula [X-Yand having only one catalytic region.

Alternatively, the ribozymes may be "polyribozymes" comprising a plurality of units and having the general formula R 1

-R

2 Rn, wherein n 1, and may have a value as high as 50 or 100. In practice, a value for of about 5 to 10 is frequent. The polyribozymes are thus constituted by a head-to-tail series of ribozymes, the monoribozyme "R" or unit, being the unit motif. In other words, it is a series of catalytic regions connected together by hybridising arms. Hereinafter, unless otherwise indicated, the aggregate of the X and X' motifs contributed by all the units of a polyribozyme, will be designated collectively as the "complementary" or "hybridising'- sequence. The polyribozyme normally acts as a "uni-molecule" against a single transcript, i.e. the cleavage sites of each of the catalytic regions are located on the same transcript.

The precise structure of the polyribozyme is in frct primarily determined by the nature of the substrate it is designed to cleave. The number of catalytic regions, their position in the complementary sequence and the distance between two consecutive catalytic regions are dependent to a large degree on the position of the "three-base target" sites in the substrate.

The "hammerhead" ribozymes cleave the substrate immediately downstream from a "target" site XXX, preferably XUX, in which X represents one of the 4 bases A, C, G, U and U represents uracil. One particularly preferred target sequence is X°UY in which XO is any ribonucleotide, U is uracil and Y J A; L.

I

WO 95/03404 PCTIEP93/01946 represents adenine, cytosine or uracil. XOUY forms part of a base pair flanking region and Y is not base paired. Preferred triplets defining X+OUY include, but are not limited to GUC, GUA, GUU, UUC and CUC. Other target sites are possible but less efficient, for example CAC, UAC and AAC. Perriman et al (Gene, 1992, 113:157) have studied extended target sites for hammerhead ribozymes. It has been found that GUC, UUC, CUC, GUA and GUU targets show equivalent rates of studies. For GUG, the normal ribozyme cannot induce cleavage, but an alteration of the stem-loop in the catalytic domain leads to the formation of a weakly active ribozyme. There are' some targets with nucleotides other than U in the center position which show significant, discernable cleavage.

In the case of the ribozymes of the "hairpin" type, a preferred target sequence is AGUC.

These target sequences are important in the construction and functioning of the polyribozymes, not only because they indicate the positions of cleavage of the substrate but also because they define the position at which the catalytic region must be inserted in the complementary sequence. In fact, each catalytic region of the polyribozyme must be situated at a site in the complementary sequence which corresponds to a XUX site of the transcript. For example, if one XUX site is situated at position 412 of the C, gene and another at position 711, a catalytic region is inserted at the position corresponding to 412 in the complementary sequence, and another at 711. In other words, the X and X' hybridising sequences which flank the catalytic domain in each unit, are chosen so as to be complementary to the bases surrounding the XUX site targeted in the substrate.

I Ir"'"T me~-rrraru~~ WO 95103404 PCTIEP93/01946 The motif XUX is a motif which occurs very frequently in the RNA sequences. For example, on average there is a GUC motif every 64 bases in a sequence having a random and equal distribution of bases. This signifies that the substrate usually contains a plurality of XUX cleavage sites. As indicated above, the catalytic regions of the polyribozymes are situated at positions of the complementary sequence which correspond to the XUX sites. However, it is not necessary to include a catalytic region for each XUX target sequence of the substrate in order to obtain an efficient cleavage according to the invention. The total number of catalytic regions included in the polyribozyme is normally equal to or smaller than the total number of XUX sites present in the transcript target. The polyribozyme variant of the invention may thus contain a very variable number of catalytic regions. For example, in the case of C, of TLCV, the polyribozyme may contain from about 2 to about 6 catalytic regions, when the target sequence is GUC. In the case in which it is decided to include a smaller number of catalytic regions in the complementary sequence than the number of XUX sites in the substrate, the choice of the sites selected may be made by respecting the following criteria a) the distance between the 2 XUX sites targeted and, consequently, between 2 catalytic regions in the polyribozyme must be long enough to enable the hybridizing arms of the polyribozyme situated between the corresponding catalytic regions to hybridize with the substrate in a stable manner and to prevent the catalytic regions hybridizing with themselves. A distance of at least 8 bases, and preferably at least g i-i a -i i i3

;I

c

A

WO 95/03404 PCT/EP93/01946 S WO 95/03404 PCTEP93/01946 13 14 bases, for example about 20 bases is particularly advantageous. Of course, this criterion must only be taken into consideration when the substrate contains XUX sites very close together. Otherwise, if the XUX sites of the substrate are separated from each other by more than 8 to 20 bases, this selection criterion is not important.

b) the XUX sites targeted are preferably situated in a part of the substrate which does not have significant secondary structure. This facilitates the access of the polyribozyme to the substrate and increases its efficacy. Three-dimensional folding analyses may be carried out.

c) the XUX sites targetecd may form part of the regions of homology conserved between different strains or variants or mutants of one and the same virus, or between different related viruses. This aspect of the invention is considered in detail later.

d) another selection criterion of the XUX sites targeted is the absence of homology with endogenous genes of the plant to be transformed. In fact, although they are rare, some viruses possess sequences which find a homology in the gcnome of plants. It is thus important to avoid XUX sites situated within such a sequence.

In the ribozymes of the invention, the hybridising X' and X motifs within any one unit are often complementary to adjacent, contiguous partions of the substrate. In this case, the ribozyme can be thought of as "symetric", and the catalytic domain acts at a unique site determined by the complementarity of its two flanking arms. A preferred

I

-4i 4. I t r -c ,i i A WO 95/03404 PCTEP93/01946 14 example of this symetric type of ribozyme is the "purely complementary" polyribozyme in which the 3' hybridising arm of a given unit and the hybridising arm of the adjacent unit are complementary to sequences which are contiguous 'in the (-)sense RNA transcript or in the DNA genome.

In other words, in this embodiment, the aggregate of the hybridising arms gives a sequence of uninterrupted complementarity to the target sequence.

This type of polyribozyme may be considered as a complementary sequence having, inserted at distinct sites in that sequence, a plurality of ribozyme catalytic regions. The complementary sequence may hybridise with the entire length of the target transcript. On the other hand, it may hybridise with only a fragment of the targeted transcript. The fragment in question must be long enough to allow the inclusion of at least 2 catalytic regions in the corresponding sequence of the polyribozyme. In general, for this variant, the length of the complementary sequence, not counting the catalytic regions (the sum of the hybridising arms), may vary from about 40 to 2000 bases. Lengths of 400 to 1000 is particularly preferred.

According to a variant of the invention, rather than being "symetrical" as described above, the ribozyme may be, or may possess at least one unit which is "asymetrical". This signifies that the X and X' hybridising arms within a given unit are I complementary to two sequences which are noncontiguous in the substrate. This in fact means that the catalytic domain of the "asymetric" unit can act at two-distinct XUX sites in the substrate, one Sbeing the XUX site flanked by the sequence Scomplementary to its 5' arm, and the other being the i ol i XUX site flanked by the sequence complementary to its 3' arm. This type of ribozyme may be specifically constructed, or may be the result of a spontaneous re-arrangement during synthesis. The locations of the sequence to which, on the one hand, the 3' flanking arm hybridises, and the sequence to which, on the other hand, the 5' flanking arm hybridises, may be separated by hundreds of bases or by as little as or 20 bases. This type of structure is advantageous since it allows a significant "economy" in catalytic regions for example five "asymetric" units can achieve the same result as 10 symetric units.

According to another highly preferred embodiment of the invention, in the polyribozyme having the formula Rn, the 3' hybridising arm of a given unit and the 5' hybridising arm of the adjacent unit are complementary to non-contiguous portions of the genome or of the (-)sense RNA transcript. This type of polyribozyme will be referred to hereinafter as a "short arm polyribozyme".

The structure of these polyribozymes is basically a sequence complementary to the target sequence in which ribozyme catalytic regions are embedded and which has undergone deletions in the complementary sequence. The distance between two catalytic regions in the polyribozyme is shorter than the distance between the two corresponding XUX sites in the target sequence. The distance between ribozymes can be reduced significantly with respect to the distance between the corresponding target sites in the substrate, for example, if two adjacent targeted XUX 1 A i' i IrV a eiMAA PCT/EP93/01946 WO 95/03404 PCT/EP93/01946 16 sites in the substrate are separated by a distance of 1000 nucleotides, the distance between the catalytic regions of the "short arm ribozyme" may be as little as 30 or 40 nucleotides. Reductions of over 90 of the length of the hybridising sequence may therefore be made. The minimum length between two adjacent catalytic regions is normally about 8 nucleotides and prefer:bly at least 20. The present inventors have shown that such shortened hybridising sequences do not, surprisingly, prevent the polyribozyme from efficiently cleaving the substrate and can, in fact, in many cases improve the efficiency of the inactivation. A For example, the reduction in the length of the complementary sequence avoids problems associated with the formation of secondary structure leading to the inactivation of the ribozyme. Thus, for a given length of ribozyme molecule, more catalytic regions may be inserted targeting more cleavage sites in the substrate.

Furthermore, the use of the short arm polyribozyme means that efficient polyribozymes may be constructed even if only parts of the sequence of the substrate are known. It is sufficient to know the Sor 15 bases surrounding an XUX target site.

Another important advantage is the possibility to use, as the shortened hybridising arms, exclusively those sequences which are conserved in different viruses, for example viruses of the same type. In this way, different viruses may be inactivated by the same polyribozyme even if the sequences between the Finally the smaller molecule allows an easier and more economical synthesis. The functional nature of S/the "short arm" ribozymes of the invention prove that, I

I:"

iL- 4 ana, in parm cuiar, geminlvjruuse, UCUKe Js a Unee LU disease resistance strategy to be developed.

One approach is to artificially suppress gene expression by antisense RNA which targets i_ i_ WO 95/03404 PCT/EP93/01946 in a polyribozyme, the different catalytic regions can act independently of each other.

Any one polyribozyme of the invention may include a mixture of "long arm" and "short arm" ribozymes, and also of "symetric" and asymetric" ribozymes.

Alternatively, it may include only long arm ribozymes, or only short arm, or only asymetric, etc... The structure of the ribozyme can therefore be optimised, and tested.

According to yet a further embodiment of the invention, the hybridising arms of the polyribozyme may be derived from at least two different types of virus. Such polyribozymes are referred to hereinafter as "chimeric polyribozymes". As an example of this type of construction, mixtures of TLCV and TYLCV derived sequences can be cited, for example the Sardinian, Israeli or Tunisian strain. This type of polyribozyme ensures the inactivation of both types of virus, if present together, or allows the use of a single construction in different geographical areas.

According to a further variant of the invention, the polyribozymes may include, between two consecutive units, a non-complementary sequence which has a length of at least 4 bases, and which is noncomplementary to the (-)sense RNA transcript or DNA genome.

The non-complementary sequence of the polyribozyme may have a precise function, for example, it may be constituted by a coding sequence which can be used to select transformants or also a sequence containing a ribozyme which acts on a substrate other than the primary target of the DNA virus or which is cis acting on a part of the polyribozyme. It typically contains a polylinker for cloning, or an adaptor to facilitate construction of chimeric polyribozyme. The

H

-i transcript showed reduced symptom development, it is possible that the transgenic plants were infertile WO 95/03404 PCT/EP93/01946 18 non-complementary sequence usually has a length comprised between 4 and 500 bases, for example 20 to 100 bases. When there is a plurality of noncomplementary sequences, they may together constitute as much as about 90% of the length of the polyribozyme, for example 50%. These non-complementary sequences normally replace portions of the complementary sequences X and but leave at least 4 complementary bases immediately next to the catalytic domain.

According to a most preferred embodiment, the ribozymes of the invention are constructed so that the hybridising arms are complementary to a region or to regions which is (are) highly conserved between variants or mutants of the same strain, between strains of the same virus type or even between viruses of different types.

Comparisons of deduced amino-acid sequences encoded by a different open-reading frames of geminiviruses, that is Vl, V2, C1, C2, C3 and C4, has been made (see for example references cited in table For the Cl replicase polypeptide, the highest homology occurs between TLCV and TYLCV-I with a homology of 83 Between TLCV and TYLCV-S there is 79 amino-acid identity over the Cl open-reading frame.

If this compa.ison is made for the Israeli, SSardinian and Tunisian isolates of TYLCV against TLCV, A similar homologies are found (see table 1).

WO 95/03404 SCTIEP93/01946 rV WO 95/03404 PCT/EP93/01946 19 TABLE I. PAIRWISE COMPARISONS OF DEDUCED AMINO-ACID SEQUENCES ENCODED BY C1 ORF OF GEMINIVIRUSES: Virus Amino-acid identity 1 TYLCV-S/TYLCV-I 77 2 TYLCV-S/TYLCV-T 3 TYLCV-S/ACMVA 74 4 TYLCV-S/ICMVA 76 TYLCV-S/ABMVA 67 6 TYLCV-S/TGI4VA 67 7 TYLCV-S/BGMVA 63 8 TYLCV-S/SqLCV 53 9 TYLCV-I/TYLCV-T 78 TYLCV-I/ACMVA 73 11 TYLCV-I/ICMVA 12 TYLCV-T/ACMVA 72 13 TYLCV-T/ICMVA 77 14 ACMVA/ICMVA 74 TLCV/TYLCV-I 83 16 TLCV/TYLCV-S 79 17 TLCV/BGM4VA 64 18 TLCV/PYMVA 68 19 TLCV/ABMVA 68 TLCV/TGMVA 69 21 TLCV/ACMVA 78 22 TLCV/BCTV 61 23 TLCV/TobYDV 24 TLCV/MSV TLCV/WDV 24 4 Lgen fo TaleFor 1 to 14, amino-acid identity is given in percent derived with the program BestFit of the UWGCG-Sequence analysis package. The word size (Ktuple) was 2, the gap weight was 2. 0 and gaplength weight was 0. 1. The program FastA yielded the same relationship.

For 15 to 25, amino-acid identity was calculated using PALIGN program of the PC/GENE sequence analysis package using the structure-genetic comparison matrix (open gap cost value, 10 unit gap cost value, ABMVA :Abutilon Mosaic Virus DNA A ACMVA: African Cassava Mosaic virus DNA- A BGMVA Bean Golden Mosaic Virus DNA A ;ICMV :Indian Cassava WO 95/03404 PCTEP93/01946 Mosaic Virus DNA A SqlCV Squash Leaf Curl Virus DNA A PYMVA Potato Yellow Mosaic Virus DNA A TGMVA Tomato Golden Mosaic Virus DNA A TYLCV-I Tomato Yellow Leaf Curl Virus Israeli isolate TYLCV-S Tomato Yellow Leaf Curl Virus Thai isolate TLCV Tomato Leaf Curl Virus BCTV Beet Curly Top Virus TobYDV Tobacco Yellow Dwarf Virus MSV Maize Streak Virus WDV Wheat Dwarf Virus.

The results summarized in the table have been given by Dry et al Gen. Virol. (1993) 74:147) and Kheyr-pour et al. (Nucl. Acid. Res. (1991) 19:6763).

The degree of sequence diversity between the 3 isolates of TYLCV and TLCV is in pronounced constrast to the usual very high sequence similarity between different geminivirus isolates or strains, for example the DNA sequences of the Kenyan and Nigerian isolates of ACMV show 96 identity and Kenyan, Nigerian and South African isolates of MSV vary maximally by about 2 In spite of the pronounced sequence diversity between the 3 isolates of TYLCV and TLCV, the present inventors carried out a comparison of the Cl RNA transcript and identified three very highly conserved regions, two of which are shown in figure 9. These regions are the following (the following numerotation is the TLCV numerotation of the complementary sense transcript) 1. 365 to 435 approximately 2. 634 to 737 3. 895 to 972 The nucleotide sequences of the C1 gene in three TLCV isolates (from Australia, Israel and Sardinia, respectively) are shown in Figure 1. The complete Snucleotide sequence of the Cl gene from TLCV is disclosed in Mullineaux et al., Virology, 193 S414-423, 1993 and Dry et al, J. Gen. Virol., 74 147-151, 1993. The Israeli isolate is disclosed by Navot et al in Virology, 185 151-161, 1991 and the WO 95/03404 PCT/EP93/01946 21 Sardinian isolate is disclosed by Khyer-Pour et al, Nucl. Acid. Res. 19 6763-6769, 1991.

Polyribozymes constructed with target sites in these conserved regions may therefore be used to ensure that all related strains or variants are inactivated. As pointed out above, if the polyribozyme is the deleted short arm version, whose hybridising arms correspond exclusively to the conserved regions, wide sequence diversity between the conserved regions does not affect the efficient hybridisation of the polyribozyme to the substrate.

According to this aspect of the invention, a "conserved region" is considered as having a 100 homology over a distance of about 20 bases. Generally speaking, the homology may be around 90 over bases. Ribozymes Rl, R4, R5 and R2 are designed so that the target sites lie within these conserved regions, as shown in the examples below.

According to this embodiment, therefore, the present invention further relates to a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least one part of a target mRNA sequence encoding the Cl gene of at least two variants of particular geminivirus and in particular at least two variants of TLCV, and wherein said catalytic region is capable of cleaving said target mRNA sequence from each of said variants thereby susbtantially reducing replication of said geminivirus TLCV, TYLC and their mutants, derivatives and variants).

The polyribozymes of the invention are usually constituted of RNA. Nonetheless, it is possible to replace some parts of the polyribozyme by DNA, for example the hybridizing arms or parts of these arms, nucleotide sequence having at least 4 bases and being Scomplementary to at least a part of either the viral genome, or the (-)sense RNA transcript of a DNA virus WO 95/03404 PCT/EP93/01946 22 or also a part of the catalytic region, in particular the "loop", provided that the catalytic activity is maintained (see, for example, the substitution of the RNA by DNA described in the international patent application WO-9119789).

As far as the catalytic region is concerned, the ribozymes of the present invention can be represented as a molecule of formula 3' Y Y (X)n, A C A U G 1 A G C G G A I I x Y' Y' 3' (I) wherein, and represent ribonucleotide sequences substantially complementary to a mRNA sequence of a DNA virus; the sum of n and n' may be the same or different; an represents a base pair between complementary ribonucleotides Y represents any ribonucleotide and each Y may be the same or different Y' and Y" represent ribonucleotides of complementary sequence along at least part of their length to allow base pairing between the oligoribonucleotides, or Y' and Y" together form a single RNA sequence wherein at least part of said sequence comprises a stem formed by base pairing between complementary nucleotides; and optionally, an additional nucleotide selected from any one of A, G, C or U is inserted after 'A.

i In another embodiment, the ribozyme is as set Iforth in formula (II) J m WO 95/03404 PCT/EP93/01946

A

A

A

G

C

Y

Y

(Y)m

Y

C

1

A

*G G Y Y

Y

(Y)m,

Y

(II)

wherein (X)n and represent ribonucleotide sequences substantially complementary to a mRNA of a DNA virus and in particular a geminivirus such as TLCV Y represents any ribonucleotide and each Y residue may be the same or different an represents a base pair between complementary ribonucleotides; n and n' are as previously defined; B represents a bond, a base pair, a ribonucleotide, or an oligoribonucleotide containing at least 2 ribonucleotides m and m' are 1 or more and may be the same or different and optionally, an additional nucleotide selected from any one of A, G, C or U is inserted after IA.

In a preferred embodiment, the ribozyme is as set forth in formula (III)

II

(X)nA

A

A

G A C G A U G C G C Y(X)n.

C

(III)

wherein (X)n and represent a ribonucleotide sequence substantially complementary to a mRNA of a DNA virus and in particular a geminivirus such a i 1 1 WO 95/03404 PCT/EP93/01946 24 TLCV Y represents any ribonucleotide and each Y residue may be the same or different an represents a base pair between complementary ribonucleotides n and n' are as previously defined.

Preferably, the DNA virus is a single stranded DNA virus. Preferably, the single stranded DNA virus is a geminivirus. Most preferably, the geminivirus is TLCV and (X)n and represent a sequence capable of hybridising to a region of C1 gene mRNA.

In a most preferred embodiment, (X)n and (X)n, hybridise to the C1 gene mRNA transcript of TLCV or TYLCV as set forth in Figure 1.

Particulary preferred ribozymes of the present invention are specifie to the Cl gene of TLCV and its variants and comprise the nucleotide sequences set forth below

GUCCAGUCGUGUAAAAK.,CAGGAGUGCCUGAGUAGUCGUAGGCUU

GAGGAAAAAAUAGAAAAGCAGGAGUGCCUGAGUAGUCAAGAAAAC

GAGUUGUAAACUACAAAGCAGGAGUGCCUGAGUAGUCUAACUUCU

and GATTTAGCTCCCTCTGATGAGTCCGTGAGGACGAAAT3TTCGGATG GAAATGTGCTCTGATGAGTCCGTGAGGACGAAACCTGGTTGGGGAT-3' Although the catalytic regions illustrated above and in Figure 7 have a conserved structure and sequence, it has been observed that some nucleotides may be deleted, inserted, substituted or modified without prejudice to the activity of the ribozyme. The invention comprises the use of these modified catalytic regions in the polyribozyme provided that their catalytic activity is conserved. This activity can be verified by using the tests described below.

LI

I Sn each unit, are chosen so as to be complementary to the bases surrounding the XUX site targeted in the substrate.

WO 95/0304 PCTIEP93/01946 For example, one or more nucleotides of the catalytic region II illustrated in formula I, II and III may be replaced by nucleotides containing bases such as adenine, guanine, cytosine, methylcytosine, uracil, thymine, xanthine, hypoxanthine, inosine or other methylated bases. The "conserved" bases C-G which together form the first base pair of the catalytic loop, can be replaced by U-A (Koizumi et al., FEBS Letts. 228, 2, 228-230, 1988).

The nucleotides of the catalytic region illustrated in Figure 7 can also be modified chemically. The nucleotides are composed of a base, a sugar and a monophosphate group. Each of these groups can thus be modified. Such modifications are described in "Principles of Nucleic Acid Structure" (Ed. Wolfram Sanger, Springer Verlag, New York, 1984). For example, the bases may bear substituents such as halogeno, hydroxy, amino, alkyl, azido, nitro, phenyl groups, etc.. The sugar moiety of the nucleotide may also be subjected to modifications such as the replacement of the secondary hydroxyl groups by halogeno, amino or azido groups or even to 2' methylation.

The phosphate group of the nucleotides may be modified by the replacement of an oxygen by N, S or C, giving rise to a phosphoramidate, pnosphorothioate and phosphonate, respectively. These latte- may exhibit Suseful pharmacokinetic properties.

The bases and/or the nucleotides of the catalytic region may also bear substituents suc-h as amino acids, i for example, tyrosine or histidine.

S

According to a variant of the invention, the Sribozyme may comprise as catalytic region one or more i 0 structures such as those illustrated in Figure 17.

This structure, called "minizyme", is described in the Sinternational patent application WO-A-9119789. It \rcatalytic regions hybridizing with tnem5seiv distance of at least 8 bases, and preferably at least 3 k j ,Hlii |i 1

I

WO 95/03404 PCT/EP93/01946 represents a catalytic region of the "hammerhead" type, the "loop" of which has be3n replaced by a "P" group. P may be a covalent link between G and one or more nucleotides (RNA or DNA, or a mixture, or even derivatives described above) or any atom or group of atoms other than a nucleotide which does not- affect the catalytic activity. When P represents a plurality of nucleotides, it may contain internal base pairings.

The sequence and the. number of nucleotides constituting the group is not critical and may vary from 1 to 20 nucleotides for erample, and preferably from 1 to 6. It is preferable to select a sequence lacking internal base pairings of the Watson-Crick type.

The catalytic activity of the ribozymes of the invention may be verified in vitro by placing the ribozyme, or a sequence which after transcription will give rise to the ribozyme, in contact with the substrate, followed by demonstration of the cleavage.

The experimental conditions for the in vitro cleavage reaction are the following a temperature comprised between 4 and 60*C, and preferably between 20 and 0 C, a pH comprised between about 7.0 and 9.0, in the presence of divalent metals, such as Mg 2 at a concentration of 1 to 100 mM (preferably 1 to 20 mM).

The polyribozyme is usually present in an equimolar ratio with the substrate, or in excess. The in vitro cleavage reactions are advantageously carried out according to the procedure described by Lamb and Hay (J Gen. Virol., 1990, 71, 2257-2264). This article also describes suitable conditions for in vitro transcription for the production of ribozymes from oligodeoxyribqnucieotides inserted into plasmids.

The in vivo \cleavage conditions are those existing naturally in 'the cell.

7 v- 1 -7

A

j i

I~

r- li..

-I,

2<'

I,

/1 7 In accordance with the embodiments and aspects of the invention as set forth above, the ribozyme is said to "hybridise" to a target mRNA sequence or to have "complementarity" hybridising arms. Such hybridisation and complementarity is definied herein as an extent of duplex formation sufficient to form a stable enough structure so that cleavage with the target triplet can occur. Depending on the target sequence, the ribozyme and the secondary structure of the mRNA, preferably less than about 5-10, more preferably less than about 3 to 5 and even more preferably less than 1 to 3 bases would be mismatched between the target mRNA sequence and one or both hybridising arms of the ribozyme. Over the whole length of the hybridising arm, not more than of mismatches should occur. Accordingly, the present invention extends to ribozymes described herein and in particular Rzl, Rz2, Rz3, Rz4 and to the polyribozymes containing them, and to any or all functional mutants, derivatives, parts, homologues or analogues thereof. Examples of such mutants include single or multiple nucleotide substitutions, deletions and/or additions to the hybridising regions and/or catalytic regions of the ribozymes provided such modified ribozymes are still functional in cleaving the target mRNA sequence.

Put in alternative terms, the present invention extends to a ribozyme having a hybridising domain and a catalytic domain, wherein the hybridising domain comprises a sequence of nucleotides substantially complementary to a sequence of nucleotides in a mRNA i molecule encoding the Cl gene of TLCV or TYLCV or which hybridises to said TLCV or TYLCV mRNA sequence in vitro under high stringency conditions and wherein said catalytic region is capable of cleaving said target mRNA sequence. This aspect of the present P.

I

WO 95/03404 PCT/EP93/01946 28 invention is conveniently determined by the extent of cleavage of the target mRNA sequence in vitro.

For the purposes of the present invention, the stringency conditions set forth in Sambrook et al, Molecular Cloning A laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, USA, pages 387-389 at paragraph 11 are considered high stringent conditions. Alternatively, medium stringency may be used involving 0.25-0.5 w/v SDS at 45* C for 2-3 hours. The alternative conditions are applicable depending on concentration, purity and source of nucleic acid molecules.

The present invention extends to genetic constructs comprising the ribozymes herein described.

These genetic constructs generally comprise a vector sequence as a vehicle for transferring the ribozyme to a host cell and a promoter sequence to direct transcription of the ribozyme and a terminator. A preferred promoter includes but is not limited to a Cauliflower Mosaic Virus (CaMV) or to a double CaMV promoter. The CaMV promoter is described by Odell et al, Nature 313 810-812, 1985. The ribozymes are generally in the complementary form such that upon transcription, the ribozyme is produced. The genetic constructs of the present invention are used to generate transgenic plants capable of constitutively, Sdevelopmentally or inducibly in response to certain stimuli) expressing the ribozymes herein described. Most preferred transgenic cells are rendered substantially resistant to TLCV infection.

The ribozymes and genetic constructs of the present invention can be conveniently tested in vivo using virus-sensitive plants. A particularly useful indicator plant is the tobacco plant. The analysis may be qualitative such as by screening for severity of

I

1 a 1 iL i symptoms or quantitative where samples are analysed, for example, by measuring the level ribozyme expression or level of target mRNA. A combination of qualitative or quantitative analyses may also be employed.

All of the known means for introducing foreign DNA into plants may be used, for example Aqrobacterium, electroporation, protoplast fusion, bombardment with a particle gun, or penetration of DNA into cells such as pollen, the microspore, the seed and the immature embryo, viral vectors such as the Geminiviruses or the satellite viruses. Agrobacterium tumefaciens and rhizogenes constitute the preferred means. In this case, the sequence coding for the polyribozyme is introduced into a suitable vector together with all of the regulatory sequences necessary such as promoters, terminators, as well as any sequence necessary for selecting the transformants.

In one approach, tobacco cells are transformed using standard procedures employing Agrobacterium with the genetic construct to be tested. Generally, Agrobacterium tumefaciens mediated transformation of tobacco is carried out essentially as described by Horsch et al., Science 227 1229-1231, 1985, although conveniently strain LBA 4404 is used and the plantlets are selected on Kanamycin at a concentration of 250 il/ml. The transformed cells are regenerated into small plants and samples removed to screen for expression. The plants are allowed to self-fertilise and to seed and the transgenic seeds are then used to generate new plants. The transgenic plants along with suitable controls are then exposed to the virus and the degree of symptom development analysed.

Alternatively or in addition to, a quantitative I

E

r t-; :i-~ji-.i r WO 95/03404 PCT/EP93/01946 assessment is made by biochemical analysis. This approach is particularly useful for screening for ribozymes against geminiviruses and in particular TLCV. Once suitable ribozyme genetic constructs are identified using this procedure, these particular constructs can then be used to generate, for example, in the case of TLCV and TYLCV, transgenic tomato plants. Similar transformation and screening procedures are employed.

The resistant nature of the transgenic plants can be tested by carrying out a self-fertilisation, or a cross with a non transformed genotype, on a primary descendant to obtain T 1 Subsequently, T 1 plants are inoculated with the DNA virus by Agroinoculation.

Degree of resistance "complete resistance" meaning total absence of symptoms, "tolerance" meaning that the plant can be infected and shows symptoms but recovers, "sensitive" meaning that the plant exhibits symptoms and replicates the virus) is then noted.

The present invention is particularly directed to transgenic tomato plants which exhibit at least some resistance to TLCV and TYLCV infection. By resistance to infection is meant a qualitative reduction in symptoms (generally due to inhibition of virus replication) by more than approximately 30 preferably more than approximately 50 and even more than approximately 70 Due to the variability of biological systems, 100 inhibition of TLCV replication is difficult to achieve although the effectiveness of the ribozyme can be enhanced by various molecular biological techniques.

According to this aspect of the present invention, there is provided a method of generating jtransgenic tomato plants exhibiting reduced symptoms following exposure to TLCV compared to non-transgenic WO 95/03404 PCT/EP93/01946 plants, said method comprising transforming tomato plant cells with a genetic construct encoding a ribozyme as hereinbefore described capable of cleaving Cl mRNA from TLCV, regenerating plants from said transformed cells, self-fertilising said regenerated plants and obtaining seeds there from and then growing transgenic plants from said seeds.

The present invention extends to transgenic plants exhibiting resistance to a plant DNA virus, more particularly a geminivirus and even more particularly TLCV. In one preferred embodiment, the transgenic plants are tomato plants. The subject invention also extends to reproductive material and seeds from such transgenic plants tomato plants). The ribozymes may be expressed constitutively, developmentally or inducibly.

The present invention is further described by reference to the following non-limiting figures and examples.

In the figures Figure 1 is a representation of the nucleotide sequences of the complementary-sense DNA strands from three different isolates of TLCV top row, TLCV (Australia) middle row, TLCV (Israel) bottom row TLCV (Sardinia). The sequence is represented in a direction.

S- Figure 2 is a schematic representation of comprising a CaMV35S-1568bp TLCV fragment (containing Rzl, Rz2 and Rz3)-CaMVpolyA expression S cassette cloned into BamHI cut Binl9. The insertion sites of the 3 ribozymes Rzl, Rz2 and Rz3 are indicated at positions 1111, 2056 and 2355. This numbering is the virion-sense numbering and corresponds to positions 1654, 711 and 412, PCT/EP93/01946 WO 95/03404 WO 95/03404 PCTIEP93/01946 32 respectively, using the (-)sense numbering as illustrated in figures 8 and Figure 3 is a schematic representation of comprising a CaMV35S-1346bp TMCV fragment (containing Rzl, Rz2 and Rz3)-CaMVpolyA expression cassette cloned into BamHI cut Binl9.

Figure 4 is a schematid representation of pRIBO7BIN comprising a CaMV35S-396bp TLCV fragment (containing Rzl and Rz2)-CaMVpolyA expression cassette cloned into BamHI cut Binl9.

Figure 5 is a schematic representation of pRIBO2BIN comprising a CaV35S-30bp TLCV fragment (containing Rzl)-CaMVpolyA expression cassette cloned into BamHI cut Binl9.

Figure 6 is a schematic representation of the location of primers used for RT-PCR analysis of ribozyme construct expression in transgenic tobacco.

Figure 7 is a schematic representation of a ribozyme model (from Haselhoff and Gerlach, Nature, 1988). Substrate RNA can have any sequence (X) flanking GUC at the cleavage site, as long as base pairing forms with the ribozyme as shown. The arrow indicates the cleavage site. Conserved bases in ribozymes are boxed. In naturally occuring hammerheads, the substrate and ribozyme portions are connected by a loop, resulting in an intramolecular cleavage.

Figure 8 shows the nucleotide sequence of the complementary-sense strand of TYLCV-S. Lower case Sletters indicate the ribozyme cleavage site. The sequence of TYLCV-S was published by Kher-Pour et al.

(Nucl. Acid Res. (1991) 19 6763) Figure 9 shows the regions conserved in the Replicase gene, betwei.n TLCV and TYLCV-S Figure 9(a) shows the regions highly conserved around ribozymes /f-1 WO 95/03404 PCT/EP93/01946 33 R1, R4 and R5 Figure 9(b) shows the regions highly conserved around ribozyme R2. means a mismatch, a gap means no nucleotide. Lower case letters indicate the ribozyme cleavage site.

Figure 10 illustrates the nucleotide sequence of the complementary strand of TLCV. Dry et al. (J.

Gen. Virol. (1993) 74 147) Lower case letters indicate the ribozyme cleavage site.

Figure 11 shows the target sequences for polyribozymes D, F and E. Lower case letters indicate the ribozyme cleavage site. Upper case letters correspond to the complementary sequences of ribozyme arms.

Figure 12 is a schematic representation of ribozyme constructs. A hatched line represents the TYLCV-S complementary-sense strand, and a solid line represents TLCV complementary sense strand. R ribozyme.

Figure 13 is a schematic physical map of binary vector pGAZE.

Figure 14 is a schematic physical map of ribozyme plasmids, pGAZE-RzA, pGAZE-polyRzC, pGAZEpolyRzD, pGAZE-polyRzE, pGAZE-polyRzF.

Figure 15(a) is a schematic representation of 1690bp TLCV C1/C2/C3 complementary fragment (containing 3 ribozymes) blunted into EcoRV cut Bluescript SK+ Figure 15(b) is a schematic representation of pRIBO5BIN 2660bp Bgl II C1/C2/C3 complementary (containing 3 ribozymes) CaMVpolyA cassette cloned into BamHI cut BIN 19; open triangles show the position of 22bp ribozyme insertions, E EcoRI H HindIII K: KpnI P PstI Sm r SmaI B BamI S1 SalI St SstI X XhoI Xb XbaI C Clal.

-iK 414-423, 1993 and Dry et al, J. Gen. Virol., 74 147-151, 1993. The Israeli isolate is disclosed by Navot et al in Virology, 185 151-161, 1991 and the

J

WO 95/03404 PCT/EP93/01946 34 Figure 16 is a schematic representation of the ribozyme constructs, showing their inter-relationship and the deletions carried out to obtain the "Shortarm" ribozymes, polyE, polyF and polyD.

Figure 17 illustrates the "Minizyme" structure (WO-A-9119789) wherein the loop of the catalytic region is replaced by an element P may be at least 1 nucleotide (ribonucleotides, deoxyribonucleotides, derivatives or a mixture), provided that the ribonucleotides of the group are not base paired by "Watson -Crick" base pairings when the sequences and and P are constituted exclusively of ribonucleotides. may also be a bond or any atom or group of atoms which do not affect the catalytic activity of the ribozyme. X has the same meaning as in formula I, II, III.

EXAMPLES

EXAMPLE I SELECTION OF TARGET mRNA OF TLCV To enable selection of a suitable target RNA, the major mRNA transcripts were identified and mapped on the circular genome of an Australian isolate of TLCV [TLCV (Australia), Mullineaux et al., Supra Dry et al, Supra]. One of the viral mRNAs derived from the complementary sense strand of the viral DNA occurred at a lower abundance than the other TLCV transcripts.

This low abundance mRNA transcript was identified as Sencoding the Cl gene, the product of which, is essential for replication of the virus. [Davies et al, Trends in Genetics, 5 77-81, 1989). The mRNA transcript also encodes three other gene products, *designated C2, C3 and C4, whose functions are not 1 1 constituted of RNA. Nonetheless, it is possible to jreplace some parts of the polyribozyme by DNA, for example the hybridizing arms or parts of these arms, WO 95/03404 PCT/EP93/01946 conclusively known. Accordingly, the low abundance mRNA encoding the C1 gene was selected as the target mRNA. The low abundance of this transcript means a higher ratio of ribozyme target sequence, thereby potentially permitting a more substantial decrease in Cl gene product.

EXAMPLE II SELECTION OF RIBOZYMES BASED ON CONSERVED REGIONS OF Cl GENE BETWEEN TLCV ISOLATES The nucleotide sequences of the complementary sense strands of three TLCV isolates [TLVC (Australia), TLCV (Israel) and TLVC (Sardinia)) were compared in order to identify conserved regions for targeting by ribozymes. The sequence comparison is shown in figure 1. Three conserved regions were identified for design of ribozymes. Two of these conserved regions are shown in figure 1. In addition to sequence comparisons, a computer program can be used to predict secondary structure of the target site to enable greater efficacy of the ribozyme.

EXAMPLE III SYNTHESIS OF RIBOZYMES TARGETING CONSERVED SEQUENCES OF C1 GENE OF TLCV Ribozyme 1 (Rzi) 3 GUCCAGUCGUGUAAAAAGCAGGAGUGCCUGAGUAGUCGUAGGCUU' GUAAGUC 51 Ribozyme 2 (Rz2) 3' GAGGAAA.AAUAGAAAAGCAGGAGUGCCUGAGUAGUCAAGAAAACU AGCUCA Ribozyme 3 (Rz3)

GAGUUGUAAACUACAAAGCAGGAGUGCCUGAGUAGUCUAACUUCUA

GUACUA 2 11 1 1 N 1 S.n another embodiment, the ribozyme is as set forth in formula 36 EXAMPLE IV GENETIC CONSTRUCTS CARRYING Rzl, Rz2 and/or Rz3 pRIBOBIN A 1568 fragment of TLCV from nucleotide 1075-2643 covering the C1, C2, C3 C4 reading frames (ORPS) was cloned into pALTER-1 (Promega). Ribozyme sequences 1, 2 3 (Rzl, Rz2 and Rz3, respectively) were chemically synthesised as described in Example III and introduced into the TLCV sequence using the Altered sites in vitro mutagenesis system (Promega). The integrity of introduced ribozyme sequences was confirmed by sequencing using the dideoxy chain termination method.

Rzl, Rz2 and Rz3 were shown to catalyse in vitro cleavage of a complementary-sense viral RNA transcript generated with 57 RPA polymerase at 50' C and 37 C.

The modified 1634 bp complementary-sense TLCV fragment containing Rzl, Rz2 and Rz3 was cloned in the antisense orientation (relative to C1 ORF transcription) between a double 35S CaMV promoter and a CaMV polyA termination sequence and the whole expression cassette introduced into the BamHI site of the multiple cloning site of the binary vector Binl9.

The resulting construct is pRIBO5BIN and is shown in figure 2.

EXAMPLE V GENETIC CONSTRUCTS CARRYING Rzl1, Rz2 and/or Rz3 pRIBO5BINDel This construct was derived from (Example IV) by deletion of a 216 bp region from the BstBI site (nucleotide 2424) to the 3'-end of the TLCV fragment (nucleotide 2643). The resulting construction is pRIiO5BINDel and is shown in figure 3.

SDNA virus and in particular a geminivirus such a WO 95/03404 PCT/EP93/01946 37 EXAMPLE VI GENETIC CONSTRUCTS CARRYING Rzl Rz2 i and/or Rz3 pRIBO7BIN This construct was derived from (Example V) by removal of a 950 bp region from the of the TLCV fragment (nucleotide 1075) to the Xhol site (nucleotide 2025). The resulting construct is pRIB07BIN and is shown in figure 4.

EXAMPLE VII GENETIC CONSTRUCTS CARRYING Rzl, Rz2 and/or Rz3 pRIBO2BIN A 52 bp fragment containing Rzl was amplified by polymerase chain reaction (PCR) from (Example IV) and cloned in the antisense orientation (relative to C1 ORF transcription) between a double CaMV promoter and a CaMV polyA termination sequence and the whole expression cassette introduced into the BamHI site of the multiple cloning site of the binary vector Binl9. The resulting construct is pRIBO2BIN and is shown in figure EXAMPLE VIII EXPRESSION OF RIBOZYME GENETIC CONSTRUCTS IN TRANSGENIC TOBACCO CELL LINES The ribozyme constructs described in Examples to 8 were tested for expression in transgenic tobacco plants using PCR analysis.

Leaf samples (150 mg) were collected from transgenic tobacco lines prior to potting out in the j glasshouse and frozen in liquid N 2 Samples were ground to a fine powder and vortexed for 30s with ml extraction buffer (containing 0.1 M Tris-HCl (pH 0.1 M NaCl, 10 mM EDTA, 1 w/v SDS and 1 v/v beta-mercaptoethanol) and 0.5 ml phenol. The WO 95/03404 PCT/EP93/01946 38 extract was centrifuged at 12 000 g for 10 mn and the supernatant fraction collected. The supernatant fraction was extracted a further time with phenol and then with phenol/chloroform The total nucleic acid fraction was precipitated at -20' C with sodium acetate/ethanol and centrifuged at 12 000 g for 10 mn.

The pellet was washed with 80 v/v ethanol, dried and resuspended in 50 pl sterile water.

First strand cDNA reactions were carried as follows. Nucleic acid samples were annealed at 65' C for 5 mn with. 100 mg of CaMV Term primer TTTACAAATACAAATACATACTAAGGGT in a total volume of il. This primer is complementary to a region within the CaMV termination sequence present in all ribozyme construct (see figure 6) transcripts produced from these transcriptions.

To the annealed template was added 5 Al of reverse trascriptase mix containing 50 mg Tris-HC1 (pH 50 mM KC1, 10 mM MgGl 2 0.5 mM spermidine, 10 mM DTT, 1 unit ribonuclease inhibitor and 2.25 units AMV reverse transcriptase. The mixture was incubated at 42' C for 60 mn followed by 94' C for 2 mn. Where indicated, control reactions were performed in which the AMV reverse transcriptase was omitted from the reaction mM Tris-HC1 (pH 1.5 mM MgCl2, 1.5 mM MgCl 2 0.1 v/v Triton X-100, 200 MM dNTPs, 250 AM CaMV Term primer (see figure 0.5 units of Taq DNA polymerase and 2 il of first strand cDNA reaction mix.

Two alternative 5'-end primers were used, the positions of which are shown in the attached figure C3 primer 5' -ACTGATCTAATTACATTGTTAATGC RIB primer 5 -GCAAGCTTCCTGAATGTTCGGAT Ina WO 95/03404 PCT/EP93/01946 39 PCR cycling conditions were 94* C for 1 mn, 50-55' C for 1 mn, 72' C for 3 mn for 15-30 cycles.

PCR products were analysed on 1.2-1.8 w/v agarose gels.

Reverse transcriptase (RT)-PCR analysis of RIBOSBIN and RIB05BINDel lines using the C3/CaMV Term primer combination produces DNA products approximately the predicted sizes i.e. 1690bp and 1450bp respectively.

PT-PCR analysis of RIB05BIN, RIBO5BINDel and RIBO2BIN lines using the RIB/CaMV Term primer combination produces DNA products approximating the predicted sizes i.e. 504bp, 264bp and 235 bp, respectively.

No PCR products were observed in control reactions no reverse transcriptase nucleic acid samples from plants transformed with vector sequences alone i.e. not containing ribozyme selqences. This demonstrates that the PCR products observed with these, primers were derived specifically from RNA transcripts of the introduced ribozyme constructs.

Predicted PCR product sizes using the C3/CaMV Term primer combination are as follows 1. RIB05BIN 1690 bp 2. RIBOSBINDel 1450 bn 3. RIBO7BIN J 4. RIBO2BIN Predicted PCR product sizes using the RIB/CaMV Term prier combination are as follows I 1 1 J 1 -v 1. RIBO5BIN 504 bp 2. RIB05BINDel 264 bp 3. RIBO7BIN 264 bp 4. RIBO2BIN 235 bp EXAMPLE IX CONSTRUCTION OF RIBOZYME GENES Pairwise comparisons of deduced amino-acid sequences encoded by Cl ORF of geminiviruses were investigated (table 1).

Alignment of nucleotide sequences of TYLCV genomes isolates from Sardinia (Kheyr-Pour et al., NAR (1991) 19 6763), Thai (Rochester et al., Virology (1990) 178 520), Israeli (Navot et al., Virology (1991) 185 151), Australia (Dry et al., J. Gen. Vir. (1993) 74 147) shows that there are three conserved regions in an internal fragment of the Cl transcript encoding the polypeptide essential to replication of the virus.

This BstBI Eco 01091 internal fragment (nt 346 to nt 982) of TYLCV-S genome was cloned into a Dra II/ Sma I digested pBluescript II SK+ phagemid (STRATAGENE).

This clone was used as template for the introduction of 2 ribozymes in the most highly conserved region.

Two and three dimensional folding analyses were also made to retain the more theoretical accessible target sites for cleavage with ribozyme.

The catalytic domain of hammerhead-type RNA (figure in this case satellite RNA of tobacco ringspot virus (STobRV), was used to design ribozymes that form, with a completely unrelated substrate RNA, a hammerhead structure in trans, so that the target RNA is specifically cleaved at the predicted site (Haseloff -and. Gerlach (1989), Gene, 82 43-52).

According to the general rules described by these authors, the only requirements for a substrate RNA to 4

:B

i 'i i f: 1 r r

L

I i-,R ~Ii WO 95/03404 PCT/EP93/01946 41 be cleaved by hammerhead-type ribozymes is the presence of the trinucleotide sequence for which self-cleavage has been described (Perriman et al., Gene (1992) 113 :157). The two positions for the hammerhead-type ribozymes retained on the most highly conserved region of the Ci transcript of TYLCV-S are shown in figures 2 and 3 position R4, nucleotide 407 (target site GUC) position R5, nucleotide 430 (target site UUC) To introduce the 22 bases of the hammerhead sequence of the satellite RNA of TobRV at these positions, the strategy of rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR) described by Kammann et al. (Nucl. Acid. Res. (1989) 17 5404) was used.

This method requires the following synthetic oligonucleotides: Oligo R4-R5 carrying the 2 hammerhead-type ribozymes

GATTTAGCTCCCTCTGATGAGTCCGTGAGGACGAAAATGTTCGGATG

GAAATGTGCTCTGATGAGTCCGTGAGGACGAAACCTGGTTGGGGAT 3' The underlined sequences correspond to the hammerhead structure of the satellite of ToRSV. Bold letters correspond to the target site.

This oligo R4-R5 was synthesized on an Applied Biosystems Model 380B DNA synthesizer.

0liqo T7 sequencing primer (Pharmacia) TTAATACGACTCACTAT 3' SOligo T3 sequencing primer (Pharmacia) j 5' ATTAACCCTCACTAAAG 3' r 1 in i I F* i, iP lii; WO 95103404 PCT/EP93/01946 In the first PCR (PCR I) step, the sequence between oligo R4-R5 and oligo T3 sequencing primer was amplified. The amplified fragment was purified on a molecular sieving column (PrimeErase Quick Tm kit, STRATAGENE). In the second PCR (PCR II) step, this amplified fragment was used itself as a primer in combination with oligo T7 sequencing primer. The PCR conditions were as follows PCR was carried out in a total reaction volume of 100 Ai containing 50 mM KC1, 10 mM Tris-HC1 pH 8.3,1.5 mM MgCl2, 300 gM dNTP each, 2 U Taq polymerase (Perkin Elmer Cetus), 40 pg template DNA, 100 pM primer each. PCR II was the same as PCR I, except that 5 4A (300 ng of amplified fragment estimated from agarose gel) assay volume of PCR I was directly used for priming. Denaturation 2 min 94°C annealing 2 min 40°C synthesis 3 min 72°C with cycles for each step.

After purification using agarose electrophoresis, the PCR product was digested with BstBI, filled in using Klenow polymerase and finally digested with Eco0109I. The resulting 679 nt fragment was cloned into a Sma I /Dra II digested Bluescript SK+ vector.

The cloning vector containing the cloned sequences was transformed into, and propagated in, the bacterial host XL1 Blue (STRATAGENE), using techniques known in the art (Maniatis, Molecular cloning, A laboratory guide, 2nd edition, 1989, Cold Spring Harbor Laboratory publishers).

The presence of the 2 hammerhead sequences of the satellite RNA of TobRV was verified by sequence analysis using T7 sequencing kit (Pharmacia). The result shows a perfect insertion of catalytic R4 and sites.

jI -I 1:: WO 95/03404 PCTIEP93/01946 43 EXAMPLE X CONSTRUCTION OF RIBOZYME PLASMIDS Plasmid pRIBO5BS shown in figure 15 was the base point for the construction of the other plasmids. This plasmid is a pBluescript SK+ vector carrying a .1690 bp end Ase I fragment which corresponds to the C1/C4/C2/C3 complementary fragment of TLCV (figure 4) bearing 3 hammerhead-type ribozymes at positions R1 (nucleotide 412, target site CpU), R2 (nucleotide 711, target site CUU) and, R3 (nucleotide 1654, target site GUA).

Plasmid pPolyribozyme E is derived from plasmid by deleting the 877bp "filled-in using Klenow Polymerase Xho I Bel I" fragment corresponding to the region between 2 hammerhead-type sequences at positions R2 and R3, and the 264 bp end Tth 1111" fragment. The Tth 111I site was filled-in using klenow polymerase. The "Tth III I HindIII (site of pBluescript SK+ vector") fragment was isolated after separation by electrophoresis on agarose gel. This fragment was cloned into EcoRI filled-in using Klenow Polymerase and Hind III sites of pBluescript SK+ vector, deleted previously from Sac I-Xba I digested using Mung Bean Nuclease fragment.

The polyribozyme E contains 434 bases and includes 3 ribozymes R1 (position 28), R2 (position 327) and R3 (position 399) as shown in figures 5 and 6 (polyR2E-R2). The size of the arms flanking the catalytic domains of the ribozymes is -d 27 nucleotides from 5' end to ribozymeRl 298 nucleotides between R1 and R2 p 71 nucleotides between R2 and R3 35 nucleotides from ribozyme R3 to 3'end.

The polyribozyme F plasmid is derived from pPolyribozyme E plasmid. The 56bp "SmaI (site in i l 27 WO 95/03404 PCT/EP93101946 44 pBluescript SK vector near 5' end) Sac I" fragment of the replicase gene of TLCV containing the ribozyme R1 was replaced with the 98bp "BstBI filled-in using klenow polymerase Sac I" fragment of replicase gene of TYLCV Sardinian isolate bearing the two ribozymes R4 and R5 as described previously. The exchanged fragments possess a region which is very highly conserved between different strains of TYLCV and TLCV.

The nucleotide sequence identity corresponds to 97 between the 365 nt to 435 nt region of TLCV and the 370 nt to 440 nt region of TYLCV-Sardinian isolate (Figure 3).

The chimeric polyribozyme F contains replicase gene fragments which have two different origins TYLCV-Sardinian isolate and TLCV-australian isolate.

The assembly of these fragments was made at the Sac I site. It is also possible to assemble the two fragments using an artificial polylinker. The inclusion of this non-complementary sequence has no deleterious effect on the catalytic activity of the polyribozyme.

The polyribozyme F contains 479 bases and includes 4 ribozymes R4 (position 59), R5 (position 83), R2 (position 372) and R3 (position 444), as shown in figures 5 and 6.

The size of the arms flanking the catalytic domains of the ribozymes is 59 nucleotides from 5' end to ribozyme R4 22 nucleotides between ribozymes R4 and R5 i 288 nucleotides between ribozymes R5 and R2 j 71 nucleotides between ribozymes R2 and R3 35 nucleotides from ribozyme R3 to 3' end.

The chimeric pPolyribozyme D is derived from pPolyribozyme F. The 206bp "SacI-Swal" fragment originating from TLCV was deleted. The Sac I site was destroyed by action of T4-DNA polymerase. The polyribozyme D contains 270 bases and includes 4 ribozymes, R4 (position 59), R5 (position 83), R2 (position 163) and R3 (position 235) as shown in figures 5 and 6.

The size of the arms flanking the catalytic domains of the ribozymes is 59 nucleotides from 5' end to ribozyme R4 22 nucleotides between ribozymes R4 and R5 79 nucleotides between ribozymes R5 and R2 71 nucleotides between ribozymes R2 and R3 35 nucleotides from ribozyme R3 to 3' end.

The sequences of polyribozyme E, F and D were verified using the T7 sequencing kit supplied by Pharmacia.

The functioning of polyribozymes E, F and D was tested in vitro in accordance with the protocol described in "Protocol and Application Book" from Promega.

No expression signals are contained in the polyribozymes. For this reason, they were placed under the control of double 35S promoter and poly(A) of RNA of CaMV.

To realize these constructions, the expression cassette composed of a double 35S promoter, Smonoribozyme R1 and poly of 35S of CaMV was isolated from pRIBO2BIN plasmid described above.

The pRIBO2BIN plasmid was digested with Sac I.

The Sac I sites were made blunt-ended using T4-DNA polymerase.

i The linearized pRIBO2BIN plasmid was then digested with Sal I, the "Sac I filled-in Sal I" fragment which contains the expression cassette was purified on agarose gel and cloned into pBluescript i i r r; rp r iii~ _7- WO 95/03404 PCTIEP93/01946 SK+ vector in "Xba I filled-in using Klenow Polymerase and Sal I" sites.

The Hind III Bam HI fragment corresponding to monoribozyme R1 was then replaced with HindIII BamHI fragments containing the polyribozymes E, F and D isolated from pPolyribozymes E, F and D respectively.

The Hind III BamHI fragment is in inverse orientation in the expression vector.

The expression cassette with polyribozymes E, F or D were cloned into the binary vector pGAZE (figure 7) derived from pGA492 (An, Plant Physiol. (1986) 81 86). The pGA 492 vector was double digested with Sac I and Sca I, made blunt-ended using T4-DNA polymerase and ligated after agarose gel purification.

The eliminated fragment corresponds to nearly the entire chloramphenicol acetyl transferase gene. The Hind III site was also converted into EcoRI site with HindIII EcoRI adaptors supplied by Stratagene. As for pGA492, pGAZE contains the cis-acting elements required for plant transformation, including T-DNA border, a selectable marker expressible in plants (kanamycin resistance), cloning sites, and a wide host range replicon. The kanamycin resistant marker is constructed from nopaline synthase control regions and neomycin phosphotransferase coding region of The pGAZE vector was digested with EcoRI and filled-in using Klenow-polymerase. The "SacI filled-in Sal I" fragments containing the expression cassettes with polyribozymes E, F or D were cloned into the.

EcoRI filled-in site of pGAZE.

The obtained recombinant binary vectors, pGAZEpolyribozyme E, pGAZE-polyribozyme F and pGAZEpolyribozyme D (figure 7) were introduced into the desarmed strain LBA4404 of Aqrobacterium tumefaciens (Hoekema et al., Nature (1983) 303 179) by direct

I

A

I:

~I

i 1:

I~

-4 1' cl~ transformation (protocol derived from Holsters et al., Mol. Gen. Genet. (1978) 163 181) For ribozyme A, which corresponds to monoribozyme R1 including the catalytic domainand flanking arms bases long, and polyribozyme C described above (example V) expression cassettes were introduced in pGAZE and/or pGA492 as mentioned above.

Thus, pGAZE-ribozyme A, pGA492-ribozyme A and pGAZE-polyribozyme C (Figure 8) were obtained. The genes of interest of all the constructions described above were transferred into tomato using Agrobacterium based co-cultivation system. Tomato transformation and regeneration was carried out as described by Fillatti et al (Biotechnology (1987) 5 726).

EXAMPLE XI MOLECULAR ANALYSIS OF TRANSGENIC PLANTS RNA analysis Total RNA is isolated from young leaves of transgenic and non-transgenic plants grown in the greenhouse according to Chandler et al. (Plant Physiol. (1983) 74 47). RNA is separated on agarose-formaldehyde gels and transferred to a nitrocellulose membrane. The blot is hybridized with labelled fragment or entire gene of interest. To check whether equal amounts of RNA were applied to each line, the nitrocellulose membrane is stained with methylene blue.

DNA analysis For Southern blot analysis, total DNA is isolated from young leaves of transgenic and non-transgenic plants grown in the greenhouse according to Dellaporta et al. (Plant Mol. Biol. Rep. (1983) 1 19), digested with restriction enzymes according to the t ^,I designated C2, C3 and C4, whose functions are not x WO 95/03404 PCT/EP93/01946 48 manufacturer's instructions, separated by electrophoresis on agarose gel and transferred to nitrocellulose by capillary action. The blot is probed with labelled fragment or entire gene of interest.

EXAMPLE XII EVALUATION OF RESISTANCE TO TYLCV FOR TRANSFORMED TOMATO PLANTS WITH THE DIFFERENT CONSTRUCTIONS BY AGROINOCULATIONS Since TYLCV or its cloned DNA are not transmitted mechanically, the agroinoculation technique (Grimsley et al., Plant DNA Infections Agents, Hohn and Schell (eds) Springer, Wien, New York (1987) pp 87-107) is used to assay to infectivity of the cloned DNA.

The TYLCV-Sardinian strain genome was inserted into Sst I site of the binary plant transformation vector pBin 19 (Stanley et al., EMBO J. (1986)5 1761) and a BamHI-fragment of about 600 bp extending from polylinker of pBin 19 through the intergenic region of TYLCV to the BamHI site at map position 152 of TYLCV was deleted. Subsequently a complete genome unit of TYLCV was inserted into the remaining Sst I site yielding a 1,8 mer of the TYLCV-genome in pBin 19. This plasmid was introduced directly into Agrobacterium tumefaciens strain LBA4404.

Agrobacterium tumefaciens cultures were grown at 28'C for about 48 hours. The cells were pelleted and washed twice with water and resuspended in 1/10 th of the initial volume of sterile water.

Young transformed tomato plants, at the 3 to 4 leaf stage, are inoculated into the petioles of the three youngest leaves with the concentrated Agrobacteria using a 18-gauge needle.

I

I

i i i i i i:-e i, i I tl-: Y Il~-U 1*Ili_ -1 :B r, ii Jd r

A-

4 w 'Tr-ii Mitfn iwf. i i"; i: k: WO 95/03404 PCT/EP93/01946 49 The plants are placed in a closed growth chamber with 16 h day light at 24 C under 70 relative humidity.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

i :i -CYCLPIIL X ciri iP ci :ir A, -4 '-4

I"

SEQUFNCE LISTING GENERAL INFORMATION:

APPLICANT:

NAME: Gene Shears Pty.Limited STREET: Level 3, 154 Military Road CITY: Neutral Bay New South Wales COUNTRY: Australia POSTAL CODE (ZIP): 2089 TELEPHONE: 612 904 0560 TELEFAX: 612 904 0561 (ii) TITLE OF INVENTION: DNA VIRUS RIBOZYMES (iii) NUMBER OF SEQUENCES: 19

S

4C4 Crr C CC (iv) COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (EPO) CURRENT APPLICATION DATA: APPLJICATION NUMBER: AU 47014/93 2 12 I k, I Is iI -L I n;* i

A_.

51 INFORMATION FOR SEQ ID NO: 1: SEQUENCE CHARACTERISTICS: LENGTH: 544 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLATE: TLCV (Australia) (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..544 OTHER INFORMATION: /note= "This sequence corresponds to figure 1, line 1"

I

It (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TTAAAGTTTG CAGAGAACTC CATGAGAATG GGGAGCCTCA TCTCCACGTG TCGAAGGCAA GTTCCAGTGC AAGAATCAAC GATTCTTCGA CCTGGTCTCC CAGCACATTT CCATCCGAAC ATTCAGGGAG CTAAGAGCTC GTCAGACGTC TGGAGAAGGA CGGAGACACC CTCGAATGGG GAGAGTTTCA GATCGATGGA GAGGGGGACA ACAATCAGCC AATGACGCTT ACGCCCAGGC GCTTAACACT CAGAGGCTCT TAACGTCCTT AGGGAATTAG CCCCTAAGGA TTATGTTTTA ATTTAAATAG TAATTTAGAT AGGATTTTTA CACCTCCGTT GGAGGTTTAT TTTTATCTTC TTCTTTTGAT CGAGTTCCAG AAGAACTCGA GGAGTGGGTC TGAAGGATGC CGCTGCGCGG CCTTTGAGAC CCATAAGTAT AGTAATAGAG

GAAC

CTTATCCAGT

CCCACCAGGT

AAGTCCTATC

CGATCTGCAA

GGAAGTAAGT

CAATTTCATA

GTTTCTCCTT

GCCGAGAATG

GGTGAGTCTA

120 180 240 300 360 420 480 540 544 r ii re a i t~oc 2 ri~ t~co kLc,.~ C3 primer R1B primer 5' -ACTGATCTAATTACATTGTTATGC 5 U-GCAAGcTTCCTGAATGTCGGAT INFORMATION FOR SEQ ID NO: 2: SEQUENCE CHARACTERISTICS: LENGTH: 544 base Dairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLATE: TLCV (Israel) (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 1. .544 OTHER INFORMATION: /note= "This sequence corresponds to figure 1, line 2"1 t 0 Oc (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: TCAAAGTTTG CAAAGAACTC CACGAGAATG GGGAACCACA TCTCCATGTG TCGAAGGCAA ATACCAATGT AAGAACCAAC GGTTCTTCGA CTTGGTATCC CAGCACATTT CCATCCGAAC ATTCAGGCAG CTAAGAGCTC AACAGATGTC TGGAGAAAGA CGGAAACTTC ATTGATTTTG GAGTTTCCCA AATCGATGGC GAGGAGGTCA GCAATCTGCC AACGACGCAT ATGCCGAAGC ACTCAATTCA CCGAGGCCCT CAATATATTA AAAGAGAAGG CCCCAAAGGA CTATATTTTA ATTTAAGTTC AAATTTAGAT AGGATTTTTA GTCCTCCTTT AGAAGTTTAT TTCTTTCTTC TTCTTTTAAT CAAGTTCCAG ATGAACTTGA AGAGTGGGTC TCGTGTATTC CGCTGCGCGG CCATGGAGAC CCATAAGTAT TGTCATTGAG GAACt

CTTATCCAAT

CCAAACAGGT

AAGACCTACG

AGATCAGCTA

GGCAGTAAAT

CAATTTCATA

GTTTCTCCAT

GCCGAGAACG

GGTGATAGCA

/4 53 INFORMATION FOR SEQ ID NO: 3: SEQUENCE CHARACTERISTICS: LENGTH: 544 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLAT',' TLCV (Sardinia) (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..544 OTHER INFORMATION: /note= "this sequence corresponds to figure 1, lilin 3." tt t It r c (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: TCAAAATTTG CAGAGAACTA CATGAAAATG GGGAACCTCA TCTCCATATT TCGAAGGAAA ATACAATTGT ACCAATCAAC GATTCTTCGA CCTGGTATCC CAGCACATTT CCATCCGAAC ATTCAGGGAG CTAAATCGAG CTCCGACGTC TCGACAAGGA CG3AGATGTT CTTGAATGGG GTACTTTCCA GATCGACGGA GGGGAGGACA ACAGACAGCC AACGACGCTT ACGCAAAGGC AATTAACGCA CGCAGGCTCT TGATGTAATT AAAGAATTAG CGCCTAGAGA TTACGTTCTA ATATAAATAG TAATTTAGAT AAGTTTTCC AGGTGCCTCC GGCACCTTAT TTTTATCTTC TTCTTTCGAT CAAGTTCCTG ATGAACTTGA ACACTGGGTT TCATGGATZ3C C.'GCTGCGCGG CCTTGGAGAC CGGTGAGTAT AGTGATTGAG

GGAC

CTCATCCAAT

CCAACCAGGT

AAGTCCTATA

CGATCTGCTA

GGAAGTAAGT

CATTTTCATA

GTTTCTCCTT

TCCGAGAACG

GGTGACAGCC

IC

CCCI

C C C I I C tC C i'i i

B

54 INFORMATION FOR SEQ ID NO: 4: SEQUENCE CHARACTERISTICS: LENGTH: 52 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: mRNA (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..52 OTHER INFORMATION: /note= "this sequence corresponds to example 3, ribozyme 1." (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: CUGAAUGUUC GGAUGCUGAU GAGUCCGUGA GGACGAAAAA UGUGCUGACC UG 52 INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 51 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear .CtL, (ii) MOLECULE TYPE: mRNA (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..51 OTHER INFORMATION: /note= "this sequence corresponds *I to example 3, ribozyme 2." SEQUENCE DESCRIPTION: SEQ ID NO: S ACUCGAUCAA AAGAACUGAU GAGCCGUGAG GACGAAAAGA UAAAAAAGGA G 51 fc P *cj RA(, ATTAACCCTCACTAAAG 3' 4 i INFORMATION FOR SEQ ID NO: 6: SEQUENCE CHARACTERISTICS: LENGTH. 52 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: mRNA (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..52 OTHER INFORMATION: /note= "this sequence corresponds to example 3, ribozyme 3." (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: AUCAUGAUCU UCAAUCUGAU GAGUCCGUGA GGACGAAACA UCAAAUGUUG AG 52 INFORMATION FOR SEQ ID NO: 7: SEQUENCE CHARACTERISTICS: LENGTH: 28 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear cie (ii) MOLECULE TYPE: cDNA c (ix) FEATURE: c NAME/KEY: misc_feature LOCATION: 1..28 OTHER INFORMATION: /note= "This sequence corresponds to example 8, CaMV Term primer." S. C (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: TTTACAAATA CAAATACATA CTAAGGGT 28 t o 9 t k* K C If C TV 56 INFORMATION FOR SEQ ID NO: 8: SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: misc feature LOCATION: 1..25 OTHER INFORMATION: /note= "This sequence corresponds to example 9, C3 primer." (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: ACTGATCTAA TTACATTGTT AATGC INFORMATION FOR SEQ ID NO: 9: SEQUENCE CHARACTERISTICS: LENGTH: 23 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA H FEATURE: H re c NAME/KEY: misc feature Si t c LOCATION: 1..23 OTHER INFORMATION: /note= "This sequence corresponds to example 9, RIB primer." SI' (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GCAAGCTTCC TGAATGTTCG GAT 23 I'

C

R" INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 93 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..93 OTHER INFORMATION: /note= "This sequence corresponds to Oligo R4-R5 of page 41" (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 14..35 OTHER INFORMATION: /note= "Hammerhead structure" (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 58..79 OTHER INFORMATION: /note= "Hammerhead structure" (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 36..37 OTHER INFORMATION: /note= "Target site" (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 80..81 OTHER INFORMATION: /note= "Target site" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: GATTTAGCTC CCTCTGATGA GTCCGTGAGG ACGAAAATGT TCGGATGGAA ATGTGCTCTG ATGAGTCCGT GAGGACGAAA CCTGGTTGGG GAT 4 6 rC it r O V V V-t V~c 58 INFORMATION FOR SEQ ID NO: 11: SEQUENCE CHARACTERISTICS: LENGTH: 17 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..17 OTHER INFORMATION: /note= "This sequence corresponds to Oligo T7 of page 41." (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: TTAATACGAC TCACTAT 17 INFORMATION FOR SEQ ID NO: 12: SEQUENCE CHARACTERISTICS: LENGTH: 17 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 1..17 tV OTHER INFORMATION: /note= "This sequence corresponds ct to Oligo T3 of page 41" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: c c ATTAACCCTC ACTAAAG 17 S t i i t e t

I,

<I i" 1 c C ft Ii 59 INFORMATION FOR SEQ ID NO: 13: SEQUENCE CHARACTERISTICS: LENGTH: 71 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLATE: TLCV (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..71 OTHER INFORMATION: /note= "This sequence corresponds to figure 9A, line 1. signifies a mismatch with respect to the sequence of figure 9A, line 2.

(ix) FEATURE: NAME/KEY: miscfeature LOCATION: 46..48 OTHER INFORMATION: /note= "ribozyme cleavage site" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: AATCAACGAT TCTTCGACCT GGTNTCCCCN ACCAGGTCAG CACATTTCCA TCCGAACATT CAGGGAGCTA A 71 I to t o CCrI A st C C I fccc r~l: tu t~ I u.

2 .t s-stla INFORMATION FOR SEQ ID NO: 14: SEQUENCE CHARACTERISTICS: LENGTH: 71 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLATE: TYLCV-S (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..71 OTHER INFORMATION: /note= "This sequence corresponds to Figure 9A, line 2. signifies a mismatch with respect to sequence of figure 9A, line 1." (ix) FEATURE: NAME/KEY: misc feature LOCATION: 36..38 OTHER INFORMATION: /note= "ribozyme cleavage site" (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 59..61 OTHER INFORMATION: /note= "ribozyme cleavage site" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: AATCAACGAT TCTTCGACCT GGTNTCCCCN ACCAGGTCAG CACATTTCCA TCCGAACATT CAGGGAGCTA A U tr c c t

C

(C

*4 C *44 Ut

CC

CUC

i 4- -Bj ,34 1 23' 4- 6-98;11:34 14/ 23

I~

61 INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 104 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLATE: TYLC (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 1..104 OTHER INFORMATION: /note= "This sequence corresponds to Figure 9B, line 1. signifies a mismatch with respect to sequence of figure 9B, line 2." (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 76..78 OTHER INFORMATION: /note= "ribozyme cleavage site" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: ATTTCATANN NTAAATAGTA ATTTAGATAN NNNTTTTNNN CCTCCNNNNN NNNNTTATGT TTCTCCTTTT TTATCTTCTT CTTTNGATCN AGTTCCNGAN GAAC cLe t ,*4I

*C

r'4 et (C C C L 6 6 C .4a p

RA%

Nro~ 4 4-.

1 1' 4- 6-98 11:34 15/ 23 62 INFORMATION FOR SEQ ID NO: 16: SEQUENCE CHARACTERISTICS: LENGTH: 111 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: INDIVIDUAL ISOLATE: TYLCV-S (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..111 OTHER INFORMATION: /note= "this sequence corresponds to Figure 9B, line 2. signifies a mismatch with respect to sequence of figure 9B, line 1." (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: ATTTNCATAN NNTAAATAGT AATTTAGATA NNNTTTTNNN NNNNCCTCCN NNNNNTTATG TTTCTCCTTT TTTATCTTCT TCTTTNGATC NAGTTCCNNN NGANNNNGAA G t~ Cc~ 4 K 4i f C

(ICC

p: Cr C 63 INFORMATION FOR SEQ ID NO: 17: SEQUENCE CHARACTERISTICS: LENGTH: 270 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..270 OTHER INFORMATION: /note= "This sequence corresponds to Figure 11A Polyribozyme D." (ix) FEATURE: NAME/KEY: misc feature LOCATION: 58..60 OTHER INFORMATION: /note= (ix) FEATURE NAME/KEY: misc feature LOCATION: 81..83 OTHER INFORMATION: /note= (ix) FEATURE: NAME/KEY: misc feature LOCATION: 161..163 OTHER INFORMATION: /note= (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 233..235 OTHER INFORMATION: /note= "ribozyrn- cleavage site" "ribozyme cleavage site" "ribozyme cleavage site" "ribozyme cleavage site" zre t~t

CL

lte I, (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: CGAAGGAAAA TACAATTGTA CCAATCAACG ATTCTTCGAC CTGGTATCCC CAACCAGGTC AGCACATTTC CATCCGAACA TTCAGGGAGC TAAATCGAAA TAGTAATTTA GATAGGATTT TTACACCTCC GTTGGAGGTT TATGTTTCTC CTTTTTTATC TTCTTCTTTT GATCGAGTTC CAGAAGAACT CGAGATCATG TATTGTATAA TGTACTAGAC TCAACATTTG ATGTAATTGA AGATCATGAT ATAAAATTTA ATTTTTATTA

A

64 INFORMATION FOi, SEQ ID NO: 18: SEQUENCE CHARACTERISTICS: LENGTH: 434 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 1..434 OTHER INFORMATION: /note= "This sequence corresponds to figure 11B Polyribozyme E." (ix) FEATURE: NAME/KEY: misc feature LOCATION: 26..28 OTHER INFORMATION: /note= "ribozyme cleavage site" (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 325..327 OTHER INFORMATION: /note= "ribozyme cleavage site" (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 397..399 OTHER INFORMATION: /note= "ribozyme cleavage site" 6 Sr

I

6t tr ~cr t Qf IC It It C (xi) SEQUENCE DESCRIPTION; SEQ ID NO: 18: GGTCTCCCCC ACCAGGTCAG CACATTTCCA TCCGAACATT CAGGGAGCTA AGACGTCAAG TCCTATCTGG AGAAGGACGG AGACACCCTC GAATGGGGAG CGATGGACGA TCTGCAAGAG GGGGACAACA ATCAGCCAAT GACGCTTACG TAACACTGGA AGTAAGTCAG AGGCTCTTAA CGTCCTTAGG GAATTAGCCC TGTTTTACAA TTTCATAATT TAAATAGTAA TTTAGATAGG ATTTTTACAC GGTTTATGTT TCTCCTTTTT TATCTTCTTC TTTTGATCGA GTTCCAGPA4 CATGTATTGT ATAATGTACT AGACTCAACA TTTGATGTAA TTGAAGATCA TTTAATTTTT ATTA

AGAGCTCGTC

AGTTTCAGAT

CCCAGGCGCT

CTAAGGATTA

;TCCGTTGGA

AAr.'GAGAT Ti,2TATAAAA INFORMATION FOR SEQ ID NO: 19: SEQUENCE CHARACTERISTICS: LENGTH: 479 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 1..479 OTHER INFORMATION: /note= "this sequence corresponds to figure 11C Polyribozyme F" tic I tI.

t(

C

SC C t Lt ri it rI I C I I t L I I1 t

III

(ix) FEATURE: NAME/KEY: misc_feature LOCATION: 58..60 OTHER INFORMATION: /note= "Ribo (ix) FEATURE: NAME/KEY: miscfeature LOCATION: 81..83 OTHER INFORMATION: /note= "ribo (ix) FEATURE: NAME/KEY: misc_feature LOCATION: 370..372 OTHER INFORMATION: /note= "ribo (ix) FEATURE: NAME/KEY: misc_featire LOCATION: 442..444 OTHER INFORMATION: /note= "ribo (xi) SEQUENCE DESCRIPTICOI SEQ ID NO: 19: CGAAGGAAAA TACAATTGTA CCAATCAACG ATTCTTCGAC C AGCACATTTC CATCCGAACA TTCAGGGAGC TAAATCGAGC T TCTGGAGAAG GACGGAGACA CCCTCGAATG GGGAGAGTTT C AAGAGGGGGA CAACAATCAG CCAATGACGC TTACGCCCAG G GTCAGAGGCT CTTAACGTCC TTAGGGAATT AGCCCCTAAG G TAATTTAAAT AGTAATTTAG ATAGGATTTT TACACCTCCG T TTTTTTATCT TCTTCTTTTG ATCGAGTTCC AGAAGAACTC G GTACTAGACT CAACATTTGA TGTAATTGAA GATCATGATA T zyme cleavage site" zyme cleavage site" zyme cleavage site" zyme cleavage site" TGGTATCCC CAACCAGGTC CGTCAGACG TCAAGTCCTA AGATCGATG GACGATCTGC CGCTTAACA CTGGAAGTAA ATTATGTTT TACAATTTCA TGGAGGTTT ATGTTTCTCC AGATCATGT ATTGTATAAT AAAATTTAA TTTTTATTA

Claims (10)

1. A rlbozyinc comprising a hybridiaing region anid a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target niRNA sequence Lranscribed from a DNA molecule associated with a ger!inivirus capable of intaciting plant cells, wherein sai~d catalytic region is capable of cleaving said taryct rnRNA sequence thereAby substantially reducing replication, infection, symiptoms and/or assemnbly of said DNA virua.

2. A ribozyme according to claim I. wherein the geminiviris is selected f rom the group consisting of Maize Streak Viri.s (MSV), Beari Gold Mosalc -Virus (BGr4V), African cassava Mosaic virus (ACMV), Chlo.T is Striate Mosaic Virus (CSMV) Tomato Yellow Leaf Curl Virus (TYLCV), Tomato Coilden Mosaic, Virus (TCGMV), Tomato Leaf Curl Virus (ThCV) and Beat Curly Top Virus isCmv.

3. A ribozyme iaccording to claim 2 wherein the geminivirus is Tomato Leaf Curl Virus (TLCV), Tomato Yellow Leaf Curl Virus (TYLCV) or a mutant, doeriv-ative or variant thereof.

4. A rib6zleme comprising af hybridising region and a .catalytic region wherein the hybridising region is capable of hybridising to at least part of 'a _target uRNA sequence transcribed 'from a vT-iron- sense DNA molecule of a gcaminivirus or a DN molecule COtIlementary to said virion-sense DMA znlecule, wherein said vatnlytic region is capable of cleaving 4- 3# 7/ 23 -67- said target ri]WA sequence thereby iaubsCafltially reducing replication, infection, symptoms and/or aoseinbly of said genipivirus. S. A ribozyme according t~o claia-, 4 wherein the inRNA transcript is in low abundance compared to other mRNA transcripts directed by Ithe virus.

6. A ribozyme according to claim 5 wherein the mRNA trange~ript i(J 1mm tUe C 1 Li, Ail, ACI, or other gene involved in the replication of a gemrinivirus gone.

7. A ribozyme according to claimn 6 wherein the C1 gene is specified by the~ complemientary- sense DWA strand' of said gemiriivirv4, 8 A ribozynL according~ to claimn 4 wherein the mRda tran.cript is from the CI, C2, C3 and/or C4 ORFS. it 9. A ribozyme according to claim 7 wherein the IC geminivirus is selected from the group consisting of Maize Streak Vir-us (MSV) Bean Gold Mosaic Virus (BGMV) African Cassava Mosaic Virusw (ACMV), Chloris Striate Mosaic Vir-us (WSW), Tomato Yello'i Leaf Curl Virus (TYLCV), Tomato Golden Mosaic Viu (TGP4V), Tomato L~eaf Curl vinis (TLCV) and Beet Curly Top Virus (AMT) preferably TTICV, TYLCV or a inutant, derivative or variant thereof. A ribozyme accrording to claim 9 wherein the hibridising region of said ribozyme is capable of hybridiaing to a zequence of ribonucleotides flanking a sequence X 0 wherein X is any ribonucleatide, U is uracil and Y is adenine, cytosine or uracil, said hybridiming region comprising a sequence of I7gleotideo NT O LIJ 4- 6-S8;11 :34 B/ 23 having ggubgtanri~l identity with a part or region of the sequence illustrated -in figure 1.

11. A ribzym accordinig to claim 10 selected from the group conOSlLirng of GUCCAOt7CGUGUMAAAACCACGAGUCC1AGAUAGUtGUAGGL-U 3'9- GAGGAAAAAAUAGAAAAUCAG0r;AGUGCCTJGAGUAGUCAAGAAAAC 3' CIAGUUGUAACIAC',iAAGCAGACUGCCUiGAGCUAACJLICU too. and GAUUACUCCCUCGAUGAGUCCG'UGAGGACGAAMUGL1CGAUC; CAAAUGUCUCUAUAUCCCuGAGGACGAAACCUGGUUQC-C4AU- 3'

12. Nucleic acid compound having endoribonu~leaoe activity and being capable of inhibiting the replication, infection. sympcom development or assembly of a geminivirus, said compound comprising at least one unit, having the general formula

51-XlI 3' X and XI t--ch represent, independently, a nucloide sequence having at least 4 bases and. being comnplementary to at least a part of either then viral geon, or the (-)sernse RM rransCrip-_ of a geminiviime 4- !3 9/ 23 4- 5-9;11693 -Y represents7 thc catalytic region of a ribozyue. 13. Nucleic aicid compound according to claim 12 compriig one "R"I unit only and having the general X, X' and Y being as previously defined. 14. Nucleic. acid compound according to claim 12, comprising a plurality of "RI, units and having the general formula4 1t V R en as preiosl dotn----an---R> ulicai omon ccrig'qcam1 r bein whrite pvoul adciie, aunde nihi anpn 1. unit are complemencary to adjacent, contiguous portions of the geniinivi.rus genome or sense RNA transcript. 16. Nucleic aicid rompound according to claims 14 and 15 Wherein tile 3' X, sequence of a given unit and the 5' x sequence of the adjacent "R"I unit are complementary tb sequences which are contiguous in the EftI genomes or sense RNA transcript. 17. Nucleic acid compound according to claim 13 or 14 characterised in that the X and X' sequences within any one WWII Unit are complementary to noxi- contiguous portionsA of thoe genonie or of the-(-)sene RNA transcript. 4- 6-98;11!34 10/ 23 3.8. Nucleic acid compound according to claim 14 wherein the 3' XI staquence ot a given ORR unit and the 51 X sequence 01 the adjacent mR unit are complementaxy to non-contiguous portions of the genonie or of the (-)menee RNA Lranscript. 19. N~ucleic acid compound according to any one of claims 12 to 1A wherein a sequence "A"l having at least 0 0 4 bases arid being non-complementary to..the viral genoone or the (-sense RNA Lranscript, is included between 2 consecutive units. Nucleic acid compound dccording to claim 19' $wherein the non-coiplemo~ntary sequence "All is a polyli1nker or a spacer, 21. Nucleic acid compound according to any of claims 14 to 20 comprisinq X and X, oequences4 omnplemenitary to the ycenonle or to the -)sense transcripts of at ledst 2 different types or is6lates of geminivirus. 22. Nucleic acid comrpound according-to any of claims 14 to 20 wherein at least one of the OR" units contains X and X, sequences which are complementary to regiona highly com3ezrved between geminivirueen. 23. Nucleic aicid compound according to any one of -elaims 12 to 22 wherein the ribozyme catalytic region 9'Y" is a hanmerhead ratalytic region. iLl NTo~ -71- 24. A ribozyme of Formula (I) A C A IU C A a I I Y Y1 Y1 wherein, and represent ribonucleotide sequences substaulLiULLY complementary to a mRNk sequence of a geminivirus the sum of n and n, may be the same or different an reprerents a base pair between complementary :ibonuacleot idea Y represents A any ribonucluotide and each Y may be the same o t t different Y, and represent ribonucleotides of complementary se~quence alonig at least parr-, of 'their length to allow baqe Paiiring between the oligoribonucleot ides, or' Y Iand Y' toger-ber form a single RHA aequence wherein at least part of said sequence comprises a stem formed by base pairing between complementary nucleotidca and optionally, an additional nucleotildc selected from any one of A, G3, C -ir U'is iniserted after I A. Fk~ -Lf'I U- CN)O§ 4- B38;1:34# 12/ 23 -72- A ribzymre according to claim 24 of formula A (I A C A C *G 0 A y *Y Y Y wherein, Mx) and represent ribonucleotide t *t sequences oubstanLially complementary to a ITIIU of a geminivirus such as TLCV or TYLCV Y represents any ribonucleotide and each Y residue may be the same or different an ropresents a base pair betwveen comrplementary ribonucleatides n r and are as previously defined H represents a bond, a base pair, a ribonucleotide or an oligoribonucleotide, containing at least 2 ribonucleoLides mr and m, are 1 or more and may be the aame or different and optionally, an additional nucleoLide selecL~d from any one of A, G, C or U is inserted after 'A. T 0T 4- 6-98;11 :34

73- 26. A ribozynic acczording to Claim 25 of Formnu1a 13/ 23 3, A A A A G A G (2 G G A tf t *4ttt 9 (III) tIC. C I C IC,. wherein, CC), and represent ribonucleotide sequences sub.8tantially complementary to a mRNA of a geminivizus such as TLCV Y represents any ribonucleotide and each Y residue may be the vame or different ;an (*)represents a base pair between couplementary ribonucleatides ;n and v, a re as previoualy defined. 27. A ribozyme according to claim 26 selected from the group consi1sting of 31- GUCCAGUCCUC;HMAAAAAGCACGAC.UGCCUGAGUAUCGJAGGCUU GUAAGUC-' GAGiGAMAAAUALAGAAAACCAGAGGCCJGAGUAGoUCAAGAAAAC LJAGCLICA- 5'1 31- GAGUJUGUAAACUACAAAGCAGGAUCCUGGWAJCjkACUUCU AGUACUA- and P. K A 4- 6-98:11!34 14/ 23 -74- So'- GAUUtJAGCUCCCLJCUGAUGAGUCCGUGAGGACGAAUOUUCGGAUG CAAUGCUCUG;AUGACUCC(-UGAGGAC!GAACCUG=UU~GAU 3'4 A gu.nctic construct: comrprining a complementary se~quence of the riboyme according to claim 1, 4, 12, 24 or 27 and a vector sequence. 29- A geneti.c consiruct accordinS to claim 28 further comprising ;Ai promoter operably linked to said complemenrary ribozyme sequence- rmth ru 3.Agenetc~i sequience melected fo h ru ftIconsisting of pxisosBIN, pRIBOSSINDel, pR.IBO7BIN, p I VpE0l2BIN, pGAZE-RzA, pGA7ZE-po1yR2zC, pGAZE-poly ZZD, pGAZE-polyRzE, p(GA7Z -polyRzF, pGA4 92 -IzA and LpqA4L2plyVziL L31. A transgenic plant comprising cells capable of reducing r'eplieation. infection. symptoms and/or assembly of a gcminivirus, said plant~ cells'-expressing a ribozyme according to any one of claims 1, 40- 12, 24 or 27. 32. A tranagenin plant according to claim 31 wherein said geiinivi rue is TLCV or TYhCV. 33. A trarisgenic plan- according to claim 32 wherein the riboynw' expres!;ed is Belected f rook the group consisting of P11305, RLBO5De1, RIBO7, RIBO2, RzA, polylzC, polyRzD, polyRzE, palyftzF. 34. A transgenic p1 anL according to any one of claims 31 to 33 wvherein' said plant is a tomato plant, Procesa for conferring resistance to a geminivirus on a planr, by Ihe int roducti on--into the plant of, a rib-o7yre_ accordingj to any one of claims \AO O ITA I 7 If 4- 6-98;11:34; 15/ 23 W~OPERUMNA 79T737. 155 416191 75 4, 12, 24 or 27. 36. Process according to claim 35, wherein the ribozyne is introduced into the plant by stable genetic transformation of a part of the plant by a DNA sequence encoding the ribozyme, followed by regeneration of a transgenic plant. DATED this 4th day of June 1998 10 GENE SHEARS PTY. LIMITED By its Patent Attorneys DAVIES COLLISON CAVE eCt 0~ 2 I p C Ce t CI. it ret tier Ctej C Cr C C t~t~ (to' t C C' C P.C 4. *4 C Cc C' 'C, 'C 'itt it.,